Page 1 of 62Immu
noGen, Inc.  
Protocol #: 0403  
FORW
ARD 1:  A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of 
Mirvetuximab Soravtansine (IMGN853) Versus Investigator ’s Choice of Chemotherapy in Women 
with Folate Receptor α−positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or 
Fallopian Tube Cancer  
Statistical Analysis Plan  
Versi
on 4.0 
Document last saved : 3-Mar-2020 1:56 PM  
Prepared for:  
 
Im
munoGen, Inc.  
830 Winter Street  
Waltham , MA 0 24 51 Prepared by:  
 
No
vella Clinical  
1700 Perimeter Park Dr.  
Morrisville, NC  27560  
Approvals  
[STUDY_ID_REMOVED]

  Page 2 of 62  
    
 
 ImmunoGen, Inc.  
  Date  
   
   
 
 ImmunoGen, Inc.  
  Date  
   
   
 
 N ovella Clinical  Date  
 
 

ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 3 of 62  
 TABLE OF CONTENTS  
LIST OF ABBREVIATIONS  ...................................................................................... 7  
1. INTRODUCTION  .................................................................................. 10  
1.1. Background ............................................................................................. 10  
2.1. Protocol Objectives  ................................................................................. 13  
2.1.1.  Primary Objective  ................................................................................... 13  
2.1.2.  Secondary Objectives  ............................................................................. 13  
2.1.2.1.  Key Secondary Objectives: ..................................................................... 13  
2.1.2.2.  Other Secondary Objectives:  .................................................................. 13  
2.1.3.  Exploratory Objectives ........................................................................... 14  
2.2. Study Endpoints ...................................................................................... 14  
2.2.1.  Primary Endpoint .................................................................................... 14  
2.2.2.  Secondary Endpoints .............................................................................. 14  
2.2.2.1.  Key Secondary Endpoints: ..................................................................... 14  
2.2.2.2.  Other Secondary Endpoints: ................................................................... 14  
2.2.3.  Exploratory Endpoints ............................................................................ 15  
2.3. Study Overview ...................................................................................... 15  
2.3.1.  Study Population ..................................................................................... 17  
2.3.2.  Power and Sample Size  .......................................................................... 17  
2.3.2.1.  Primary Endpoints .................................................................................. 17  
2.3.2.2.  Power for Key Secondary Endpoints ...................................................... 18  
2.3.3.  Treatment Randomization and Stratification  .......................................... 18  
2.3.4.  Blinding and the BIRC ........................................................................... 19  
2.3.4.1.  BIRC ....................................................................................................... 19  
2.3.5.  Assessment Schedule  .............................................................................. 20  
2.4. Interventions ........................................................................................... 20  
2.4.1.  Clinical Trial Material  ............................................................................ 20  
3. GENERAL ANALYTICAL CONSIDERATIONS  ............................... 21  
3.1. Data Sources  ........................................................................................... 21  
3.2. Definition of Baseline  ............................................................................. 21  
3.3. Missing Data  ........................................................................................... 21  
3.4. Multiple Assessments for the Same Assessment Time Point  ................. 22  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 4 of 62  
 3.5. Multiple Study Centers ........................................................................... 22  
3.6. Covariate Adjustment in Primary Analysis  ............................................ 22  
3.7. Sample Size Reassessment  ..................................................................... 22  
3.8. Interim Analyses  ..................................................................................... 22  
3.9. Timing of Final Analysis  ........................................................................ 23  
3.10.  Test Sizes  ................................................................................................ 23  
3.11.  Hypothesis Testing and Multiple Comparisons ...................................... 23  
3.11.1.  Primary Endpoints .................................................................................. 23  
3.11.2.  Key Secondary Endpoints ....................................................................... 24  
3.12.  Analysis Populations .............................................................................. 25  
3.12.1.  Screened  .................................................................................................. 25  
3.12.2.  ITT Population ........................................................................................ 25  
3.12.3.  Per Protocol Population .......................................................................... 26  
3.12.4.  Response-Evaluable Population ............................................................. 26  
3.12.5.  CA-125-Evaluable Population ................................................................ 26  
3.12.6.  Safety Population .................................................................................... 26  
3.13.  Data Display Characteristics  ................................................................... 26  
4. PATIENT ACCOUNTABILITY  ........................................................... 28  
4.1. Patient Characteristics  ............................................................................ 28  
4.1.1.  Demography ........................................................................................... 28  
4.1.2.  Height and Baseline Weight, AIBW, and Body Surface Area ............... 28  
4.1.3.  Medical History  ...................................................................................... 28  
4.1.4.  Disease Characteristics, Prior Therapy, and Gene Mutations  ................ 29  
4.2. Patient Disposition  .................................................................................. 29  
4.2.1.  Screened and Enrolled Patients  .............................................................. 29  
4.2.2.  ITT, Safety Disposition .......................................................................... 29  
4.2.3.  Protocol Deviations and Population Inclusions ...................................... 30  
5. EFFICACY ANALYSES  ....................................................................... 31  
5.1. Efficacy Outcomes  .................................................................................. 31  
5.1.1.  Best Overall Response  ............................................................................ 31  
5.1.2.  CA-125 Response ................................................................................... 31  
5.1.3.  DOR  ........................................................................................................ 31  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 5 of 62  
 5.1.4.  ORR  ........................................................................................................ 32  
5.1.5.  OS ........................................................................................................... 32  
5.1.6.  PFS .......................................................................................................... 32  
5.1.7.  RECIST -Related Endpoints – BIRC or Investigator’s Assessment ....... 33  
5.1.8.  Time to Response ................................................................................... 33  
5.1.9.  PFS2  ........................................................................................................ 33  
5.2. Primary Efficacy Outcome Analysis  ...................................................... 34  
5.3. Secondary Efficacy Analyses  ................................................................. 35  
5.4. Exploratory Efficacy Analyses ............................................................... 36  
5.5. Efficacy Analysis on Subgroups of Patients ........................................... 37  
5.6. Additional Sensitivity Analyses  ............................................................. 37  
5.7. Strategies for Pooling Stratification Factors  ........................................... 41  
5.7.1.  Rationale for pooling approach .............................................................. 42  
5.8. Prognostic and Predictive Value of FRα Expression on PFS BIRC ........... 42  
5.9. Other Efficacy -related Summaries  ......................................................... 42  
6. SAFETY ANALYSES  ........................................................................... 44  
6.1. Exposure ................................................................................................. 44  
6.2. AEs ......................................................................................................... 45  
6.2.1.  Fresh Biopsy Patient TEAE .................................................................... 48  
6.2.2.  Infusion- related Reactions  ...................................................................... 48  
6.3. Clinical Laboratory Results  .................................................................... 48  
6.4. Vital Signs  .............................................................................................. 49  
6.5. ECGs  ....................................................................................................... 49  
6.6. Concomitant Medications ....................................................................... 50  
6.7. Concomitant Procedures ......................................................................... 51  
6.8. Ophthalmic Examinations  ...................................................................... 51  
6.9. Ocular Symptom Assessments  ............................................................... 51  
6.10.  Corticosteriod and Lubricating Eye Drop Compliance .......................... 52  
6.11.  Transfusions ............................................................................................ 52  
6.12.  Physical E xamination  ............................................................................. 52  
6.13.  Pulmonary Function Tests ...................................................................... 52  
6.14.  Pulse Oximetry  ....................................................................................... 52  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 6 of 62  
 6.15.  ECOG PS  ................................................................................................ 52  
6.16.  ECHOCARDIOGRAM/MULTIPLE GATED ACQUISITION SCANS
 ................................................................................................................ 52  
7. PRO ......................................................................................................... 53  
8. IMMUNOGENICITY  ............................................................................ 54  
9. BIOMARKERS  ...................................................................................... 55  
10. PHARMACOKINETICS  ....................................................................... 56  
REFERENCES  .......................................................................................................... 57  
APPENDIX 1:  TEMPLATE SAS® CODE  .............................................................. 58  
APPENDIX 2:  MONTE -CARLO SIMULATION REPORT  ................................. 60  
 
LIST OF TABLES  
Table 1:  History of Protocol Amendments ........................................................... 10  
Table 2:  Dosing and Dosing Schedule for Phase 3 Portion .................................. 20  
Table 3:  Analysis Populations .............................................................................. 25  
Table 4:  PFS Definitionsa ..................................................................................... 32  
Table 5:  PFSA INV Definitionsa .............................................................................. 38  
Table 6:  PFSB  BIRC Definitionsa ............................................................................ 39  
Table 7:  PFSR BIRC Definitionsa ............................................................................. 40  
Table 8:  Pooling of Stratification Factors  ............................................................. 42  
Table 9:  Summary of Monte- Carlo Simulations  ................................................... 62  
 
LIST OF FIGURES  
Figure 1:  Study Design Schema ............................................................................. 16  
Figure 2:  Study Period Schema .............................................................................. 17  
Figure 3:  Hochberg Procedure ............................................................................... 24  
 
 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 7 of 62  
 LIST OF ABBREVIATIONS  
Abbreviation or 
Specialist Term  Explanation  
ADA  Anti-drug antibodies  
AE  Adverse event  
AESI  Adverse event of special interest  
AIBW  Adjusted ideal body weight  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase 
BIRC  Blinded Independent Review Committee 
BOR  Best overall response 
BRCA  Breast cancer susceptibility gene  
BSA  Body s urface a rea  
CA-125 Cancer antigen 125  
CI Confidence interval 
CMH Cochran- Mantel -Haenszel test  
CR  Complete response 
CTCAE  Common Terminology Criteria for Adverse Events  
DOR  Duration of response  
ECG  Electrocardiogram  
ECHO  Echocardiogram 
ECOG PS  Eastern Cooperative Oncology Group Performance Status 
eCRF  Electronic case report form  
EOC  Epithelial ovarian cancer  
EORTC  European Organisation for Research and Treatment of Cancer 
FcγR  Fc gamma receptor  
FRα  Folate receptor alpha  
FOSI  FACT -ovarian symptom index  
GCIG  Gynecologic Cancer Intergroup  
IC  Investigator ’s choice/selected standard -of-care chemotherapy   
IDMC  Independent Data Monitoring Committee  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 8 of 62  
 Abbreviation or 
Specialist Term  Explanation  
IHC Immunohistochemistry  
IMGN  ImmunoGen  
INV Investigator 
ITT  Intent- to-treat  
MDR1  Multi -drug resist ant gene 
MedDRA  Medical Dictionary for Regulatory Activities  
MTD  Maximum tolerated dose  
MUGA Multigated acquisition scan  
ORR  Objective r esponse rate  
OS  Overall survival  
Pac Paclitaxel  
PD  Progressive d isease  
PFS  Progression- free survival  
PFS2  Time to second d isease progression 
PgP P-glycoprotein  
PK  Pharmacokinetics  
PLD  Pegylated l iposomal doxorubicin  
PR  Partial r esponse  
PR interval  Pulse rate interval  
PRO Patient reported outcomes  
PT Preferred term  
Q3W  Every 3 weeks  
Q4W  Every 4 weeks  
QoLP  Primary endpoint for quality of l ife 
QRS  Part of electrocardiographic wave representing ventricular depolarization  
QT The length of time it takes the electrical system in the heart to repolarize, 
adjusted for heart rate  
QTc Corrected QT interval  
QTcF  Corrected QT using Fridericia’s formula 
RECIST  Response Evaluation Criteria in Solid Tumors  
RMST  Restricted mean s urvival t ime 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 9 of 62  
 Abbreviation or 
Specialist Term  Explanation  
RR Respiratory rate  
SAE  Serious a dverse event  
SAP  Statistical analysis p lan  
SOC  System organ class  
TBL  Total bilirubin  
TEAE  Treatment -emergent adverse e vent  
Topo Topotecan 
TTR  Time to response 
ULN  Upper l imit of normal  
WHO Drug  World Health Organization Drug Dictionary 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 10 of 62  
 1. INTRODUCTION 
1.1. Background  
The Forward 1 study IMGN853-0403 was initiated during the dose-expansion stage of study 
IMGN853-0401, a first- in-human study of single-agent mirvetuximab soravtansine (also 
known as IMGN853). 
During the dose- escalation stage of study IMGN853 -0401, two dosing schedules were 
evaluated: Schedule A  (IMGN853 administered on Day 1, with cycles repeating every 21 
days [ Q3W ]) and Schedule B  (IMGN853 administered on Days 1, 8, and 15, with cycles 
repeating every 28  days [modified weekly]). D ose expansion began  once the Schedule A  
maximum tolerated dose ( MTD ) was  identified and a dose was selected for further 
exploration. Schedule B evaluation was stopped prior to identifying the MTD. Study IMGN853 -0401 identified the recommended Phase 2 dose of single- agent 
mirvetuximab soravtansine in patients with e pithelial ovarian c ancer (EOC) and other folate 
receptor alpha ( FRα)-positive tumors to be 6.0 mg/kg adjusted ideal body weight (AIBW) 
administered on Day 1 of a 21- day cycl e. 
Study IMGN853 -0403 was initially opened as a Phase 2 study to further evaluate the 2 
dosing schedules of mirvetuximab soravtansine (Q3W and Q4W). Following emerging data 
from study IMGN853 -0401, IMGN853-0403 was placed on hold and redesigned to be a 
randomized, open- label , Phase 3 study to evaluate the safety and efficacy of  mirvetuximab 
soravtansine (IMGN853) versus Investigator ’s choice (IC) of chemotherapy in women with 
FRα−positive advanced EOC , primary peritoneal cancer, or fallopian tube cancer.  
The protocol for study IMGN853 -0403 describes the general approach to the analysis of 
study data. This statistical analysis plan  (SAP)  describes the additional detail needed to 
complete such an analysis.  Table, figure, and listing shells will be supplie d in an 
accompanying document. 
This SAP is based on Amendment 8A of Protocol 0403.  
A brief history of protocol amendments is presented in Table 1 . 
Table 1: History of Protocol Amendments  
Version  Approval Date Salient Changes ( if any )* 
Original Protocol  18 August 2015  
Amendment 1  01 September  2015 Secondary objectives for Stage 1 were revised . 
Amendment 2  23 Septe mber 2015 No changes that require accommodation in this 
analysis plan.  
Amendment 3  20 Octo ber 20 15 Modification of the CA -125 assessment schedule  
Amendment 4  01 February 2016 No changes that require accommodation in this 
analysis plan.  
Amendment 5  17 August 2016 The trial has been changed from a P hase 2 study 
to a Phase 3 study , and limited to  women with 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 11 of 62  
 Version  Approval Date Salient Changes ( if any )* 
FRα-positive advanced EOC, primary peritoneal 
cancer , or fallopian tube canc er. The title of the 
study was revised to reflect these changes, and 
Exclusion C riterion 1 for male patients was 
added.  
Stage 1 of the study has been closed for enrollment . The dosing schedule for Arm 1 
(IMGN853) of  Stage 2 was updated to 6mg/kg 
AIBW Q3W.  
Chemotherapy agents for the IC (Arm 2) chemotherapy were updated to include only Pac, 
PLD , and Topo. 
Randomization stratification factors have been 
revised to include  number of prior lines of 
therapy, FR α levels,  and IC chemotherapy, while 
BRCA mutation s tatus has been excluded. 
Central radiology reviews by a BIRC were added 
to assess tum or response in addition to the 
Investigator ’s radiology assessment.  
The primary endpoint for Stage 2 was revised . 
PFS as assessed by the BIRC is the primary endpoint. The sample size has been updated to reflect the change in the primary endpoint.  
An interim futility analysis has been added with 
rules for study termination. 
The secondary objectives for Stage 2 were 
updated to include ORR, DOR by BIRC and 
Investigator, and PFS as assessed by the 
Investigator. 
Soluable FR α level in blood was added as an 
exploratory endpoint. Patients on IC chemotherapy will have the option 
to cross over to the IMGN853 arm after 
BIRC-confirmed PD. 
A window for start of treatment from 
randomization was added ; Cycle 1 Day 1 should 
be within 7 calendar days of randomization.  
PRO questionnaires to be used in the study have been revised to include EORTC QLQ -C30, 
EORTC QLQ -OV28 , eight- item FOSI , and 
EQ-5D-5L questionnaires instead of the FACT -O 
questionnaire. 
Statistical tests for PRO s were added.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 12 of 62  
 Version  Approval Date Salient Changes ( if any )* 
Collection of TEAEs has been revised to events 
collected from the time of informed consent until 
30 days after the patient’s last study treatment.  
Pneumonitis was added as an AESI for 
IMGN853. 
Requirement for post- dose ECGs as well as 
triplicate ECGs were removed.  
Requirement for pulse oximetry assessment was 
removed. 
Amendment 6  19 September 2016  No changes that require accommodation in this analysis plan.  
Amendment 7  04 November 2016 Optional crossover from IC chemotherapy  to 
IMGN853 after BIRC-confirmed PD  was 
removed. 
PFS2 was added as an exploratory endpoint 
Amendment 8  08 May 2017  No changes that require accommodation in this 
analysis plan.  
Amendment 8A (North America)  25 Sep tember 2017 The protocol was amended to add the possibility 
for the collection of urine samples from patients 
receiving IMGN853 at designated sites in North 
America . The exploratory objectives of the 
protocol have been updated. However, the analysis of the  urine samples will be conducted 
under the separate PK analysis plan.  
*Changes expected to require accommodation in analysis plan.  
AESI  = adverse event of special interest; AIBW  = adjusted ideal body weight; BIRC  = Blinded Independent 
Review Committee; BRCA  = breast cancer susceptibility gene; CA -125 = cancer antigen 125; DOR  = duration 
of response; ECG  = electrocardiogram; EOC  = epithelial ovarian cancer; EORTC  = European Organisation for 
Research and Treatment of Cancer; FOSI = FACT -ovarian symptom index; FR α = folate receptor alpha; 
IC = Investigator’s choice; ORR  = overall response rate; Pac = paclitaxel; PD  = progressive disease; 
PFS = progression- free survival; PFS2  = time to second disease progression; PK  = pharmacokinetic(s); 
PLD  = pegylated liposomal doxorubicin; PRO  = patient- reported outcome; QLQ  = Quality of Life 
Questionnaire; TEAE  = treatment -emergent adverse event; Topo = topotecan.  
This SAP will govern the analysis of study data. The plan for the primary efficacy analysis 
may be modified until the time of the interim analysis . The plan  for all other analyses may be 
modified until the time of database lock . Any deviations from the SAP  will be documented as 
such in the study report.  
The Phase 3 portion of the study is  the main focu s of this SAP  and will be refered to as 
‘study’, information included that specifically relates to a Stage 1 topic is designated as such .  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 13 of 62  
 2. STUDY DESIGN  
2.1. Protocol Objectives  
2.1.1. Primary  Objective  
• To compare the progression- free survival (PFS) of patients  randomized to 
IMGN853 versus selected standard-of- care chemotherapy  (IC) , as assessed by the 
Blinded Independent Review Committee ( BIRC) in the Intent- to-treat (ITT) 
population (defined in Section  3.12.2)  and in the high- FRα subgroup (≥  75% of 
tumor staining at ≥  2+ intensity). 
2.1.2. Secondary  Objectives  
2.1.2.1. Key Secondary  Objectives : 
• To compare the objective response rate ( ORR ) of patients randomized to 
IMGN853 versus selected standard-of- care chemotherapy  (IC) . 
− Primary analysis of ORR will be based on BIRC assessments. ORR based on 
Investigator ’s assessment will be analyzed as sensitivity analysis . 
• To compare the overall survival ( OS) of patients randomized to IMGN853 versus 
selected standard -of-care chemotherapy  (IC). 
• To compare the primary patient reported outcomes (PRO) endpoint using 
QLQ-OV28 assessments from patients randomized to IMGN853 versus selected standard -of-care chemotherapy (IC) as described in Protocol Section  11.7.  
2.1.2.2. Other Secondary Objectives:  
• To compare the safety and tolerability of IMGN853 with that of selected standard -of-care chemotherapy (IC). 
• To compare the duration of response (DOR) of patients randomized to IMGN853 versus selected standard -of-care chemotherapy  (IC). 
− Primary analysis of DOR will be based on BIRC assessments. DOR base d on 
Investigator ’s assessment will be analyzed as sensitivity analysis . 
• To compare the cancer antigen 125 ( CA-125) response rate per Gynecologic 
Cancer Intergroup (GCIG) CA -125 criteria of patients randomized to IMGN853 
versus selected standard -of-care chemotherapy (IC) . 
• To compare the PFS of patients randomized to IMGN853 versus selected standard -of-care chemotherapy  (IC) , as assessed by the Investigator. 
• To evaluate the pharmacokinetics (PK) of IMGN853. 
• To assess the immunogenicity of IMGN853 (anti-drug antibodies, ADA). 
• To assess PRO  using the European Organisation for Research and Treatment of 
Cancer ( EORTC ) Quality of Life Questionnaire ( QLQ)-C30, EORTC 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 14 of 62  
 QLQ-OV28, EQ -5D- 5L, and eight- item FACT -ovarian symptom index (FOSI) 
questionnaires.  
2.1.3. Exploratory Objectives  
• To evaluate potential biomarkers in blood and tumor tissue that might pr edict 
response to IMGN853.  
• To compare the time to second disease progression (PFS2) of patients randomized 
to IMGN853 versus selected standard-of- care chemotherapy (IC) . 
• To identify DM4 metabolites in urine . 
2.2. Study Endpoints  
2.2.1. Primary  Endpoint  
• PFS: the time from the date of randomization until the time of death or 
progressive disease ( PD), as assessed by the BIRC  (PFS BIRC): 
− In all patients randomized to the study.  
− In patients with high FR α level ( ≥ 75% of tumor staining at ≥  2+ intensity).  
2.2.2. Secondary  Endpoints  
2.2.2.1. Key Secondary  Endpoints : 
• ORR per Response Evaluation Criteria in Solid Tumors ( RECIST ) Version  1.1 
criteria as assessed by BIRC . 
• OS: the time from date of randomization until the date of death . 
• Primary PRO endpoint using the QLQ-OV28 questionnaire as described in Protocol S ection  11.7.  
2.2.2.2. Other Secondary  Endpoints : 
• Treatment -emergent adverse events (TEAEs) and laboratory test results, physical 
examination, electrocardiograms ( ECGs ), or vital signs. 
• Gynolocologic Cancer Intergoup CA -125 criteria clinical response rate. 
• Time -to-event endpoints: 
− PFS as assessed by Investigator . 
− DOR : the time from first objective response ( complete response[CR] /partial 
response[PR] ) to the time of PD  among those who have achieved a PR  or 
CR), as assessed by BIRC .  
− DOR as assessed by the Investigator. 
• PK parameters of IMGN853.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 15 of 62  
 • Immunogenicity of IMGN853: ADA. 
• Patient scores on  EORTC QLQ- C30, EORTC QLQ -OV28 , EQ-5D-5L , and 
8-item FOSI q uestionnaires. 
2.2.3. Exploratory Endpoints  
• Evaluate association of breast cancer susceptibility gene ( BRCA ) mutation status 
in tumor tissue and FR α expression level with anti-tumor activity of IMGN853. 
• Evaluate the association of anti -tumor activity and/or safety with the following: 
− Mutational status and  other genomic alterations in tumor samples .  
− Activation status of oncogenic pathways in tumor samples.  
− Expression of drug transporters such as multi-drug resistant gene 1 ( MDR1 ) 
(ie, P-glycoprotein [PgP] ) as well as other proteins that may influence anti-
tumor activity or safety . 
− Blood-based biomarkers (such as soluble FR α). 
− Genotyping of Fc gamma receptor ( FcγR). 
• PFS2, as assessed by the Investigator : the time from randomization to  the time of  
second PD or death. 
• Qualitative analysis of DM4 metabolites in urine. 
2.3. Study Overview   
This study is designed to compare the efficacy of IMGN853 to that of selected 
standard -of-care chemotherapy ( IC) in women  with platinum- resistant advanced EOC, 
primary peritoneal cancer , or fallopian tube cancer.  
Patients will be stratified by number of prior lines of treatment (1 or 2 vs 3), FR α levels 
(≥ 75% tumor staining at ≥  2+ intensity  [high] vs ≥  50% and < 75% tumor staining at > 2+ 
intensity  [medium] ), and IC chemotherapy ( paclitaxel [Pac], pegylated liposomal 
doxorubicin ( PLD ), or topotecan [ Topo]). Patients will be randomized 2:1 into 1 of 2 arms as 
follows ( Figure 1 ):  
• Arm 1: IMGN853 6mg/kg AIBW Q3W.  
• Arm 2:  IC chemotherapy (weekly paclitaxel every 4 weeks  [Q4W] , PLD 
administered once Q4W , or topotecan administered either on Days 1, 8, and 15 
Q4W  or for 5 consecutive days Q3W ).  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 16 of 62  
 Figure 1: Study Design Schema  
Arm 1: IMGN853
 6mg/kg
AIBW Q3W 
Arm 2: Investigator’s Choice 
Chemotherapy (Pac, PLD, or Topo)Randomization
2:1 assessed by BIRCPD
PD
 
AIBW = adjusted ideal body weight; BIRC = B linded Independent Review Committee; Pac = paclitaxel; 
PD = disease progression; PLD  = pegylated liposomal doxorubicin; Q3W  = every 3 weeks ; Topo: topotecan. 
Patients will continue to receive study treatment until they present with PD per RECIST 
Version  1.1, (as assessed by the BIRC), develop unacceptable toxicity, or withdraw consent, 
whichever comes first, or until the Sponsor terminates the study.  
Tumor assessments, including radiological assessments by computerized tomography or 
magnetic resonance imaging scans , will be performed at screening and subsequently every 
6 weeks (± 1 week) for the first 36 weeks then every  12 weeks (± 1 week) until PD per 
RECIST Version  1.1, death, or the initiation of subsequent anti- cancer therapy, whichever 
occurs first . All patients will be follow ed every 3 months (± 2 weeks) for survival until death, 
patient is lost to follow -up, patient  withdraws consent for survival, or until End of Study, 
whichever comes first . 
The study consists of a Screening period, a Treatment period , an End- of-Treatment visit, and 
a Follow-up period. See Figure 2. 
 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 17 of 62  
 Figure 2: Study Period Schema  
EOT  = end of treatment; Pac = paclitaxel; PLD  = pegylated liposomal doxorubicin; Q3W  = every 3 weeks ; 
Topo = topotecan.  
2.3.1. Study Population 
All patients must have 1 of the following pathologically  documented, definitively diagnosed 
tumor types: advanced platinum- resistant EOC, primary peritoneal cancer, or fallopian tube 
cancer . Patients must also have  the following: 
• At least 1 lesion that meets the definition of measurable according to RECIST 
Versi on 1.1.  
• Received at least 1 but no more than 3 prior systemic lines of anti- cancer therapy .  
• Confirmation of FR α positivity by immunohistochemistry ( IHC) (≥ 50% o f tumor 
staining at ≥  2+ intensity) in archival or fresh biopsy tumor sample.  
See S ection  3.1 of the protocol for a complete list of the inclusion/exclusion criteria. 
Patients who have consented to the study and have been randomized  are considered enrolled . 
Patients who are issued a patient number, but who do not successfully complete the screening 
process and who do not get randomized will be considered screen failures. Patient numbers assigned to patients who screen fail will not be re -issued. 
2.3.2. Power and Sample Size  
2.3.2.1. Primary E ndpoints  
The study has 2 primary endpoints , PFS as assessed by  BIRC in all randomized patients and 
PFS as assessed by BIRC in the FR α high-expression subgroup. The study is designed to test 
the null hypothesis that the survival function for PFS is the same between the IMGN853 arm 
and the IC chemo therapy arm versus the alternative hypothesis that the survival function for 
PFS is different between the IMGN853 and I C chemo therapy  arms. The Hochberg procedure 
will be used to control the overall type I error (see  Section  3.11 Hypothesis Testing and 
Multiple Compa risons for further details ).  
Approximately 333 patients will be randomized 2:1 (222 to  the IMGN853 arm and  111 to  the 
IC arm) over a period of approximately 21 months across approximately 130 study centers globally. The final analysis will be conducted when at least 236 PFS events are observed.  

ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 18 of 62  
 An interim futility analysis will be conducted when  at least 80 PFS events have been 
observed. The study will be terminated for futility at interim analysis if the observed hazard 
ratio [IMGN853 to IC chemotherapy ] is greater than 1 in all randomized patients and  in the 
FRα high-expression subgroup.  
The study will have 91% power to detect a hazard ratio of 0.583 in the FR α high-expression 
subgroup and 96% power in all randomized patient s at a study -wise alpha level of 5% ; the 
study will have a 39% probability of stopping for futility at interim analysis under the null hypothesis.  
Sample size and power were determined by simulations using SAS
® software with the 
following assumptions:  
• Median PFS for the IC arm is 3.5 months. 
• Median PFS for the IMGN853 arm is 6 months. 
• Exponential distribution for both event and censoring processes. 
• Ratio of FR α high to FR α medium is 2:1 .  
• Annual censoring rate is 20% in both arms. 
2.3.2.2. Power for K ey Secondary E ndpoints  
ORR as assessed by BIRC   
With a sample size of 333 (222 in the IMGN853 arm and 111 in the IC chemo therapy  arm), 
the study will have a power of 89% to detect a 17% difference in ORR (35% in IMGN853 vs 
18% in IC chemotherapy ). 
OS 
At the final analysis of PFS, the study will have 29% power to detect an OS hazard ratio of 0.778, assuming the median OS for IC chemotherapy is 14 months. 
Primary PRO endpoint  
Number of patients achieving at least a 15% improvement on the QLQ-OV28 
abdominal/ gasto intestinal symptom subscale [I tems 31-36] at the Week 8/9 assessment): This 
endpoint will be analyzed using a responder approach. Assuming a 90% compliance rate in 
the PRO endpoint, the study will have a power of 86% to detect a 15% difference in response rate for the primary PRO endpoint (25% in IMGN853 versus 10% in IC chemotherapy ).  
2.3.3. Treatment Randomization and Stratification  
The treatment randomization schedule was  developed by Y Prime . Patients will be 
randomized 2:1 into 2 groups, as follows: 
• Arm 1: IMGN853 six  mg/kg AIBW Q3W.  
• Arm 2: IC chemotherapy (weekly Pac Q4W, PLD Q4W , or Topo administered 
either on Days 1, 8, and 15 Q4W  or for 5 consecutive days Q3W   
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 19 of 62  
 Randomization will be stratified as follows: 
• Number of prior lines of therapy (1 or 2 vs 3). 
• FRα levels ( high, defined as ≥  75% of tumor staining at ≥  2+ intensity vs medium, 
defined as ≥  50% and < 75% at ≥  2+ intensity).  
• IC chemotherapy (Pac, PLD , or Topo). 
The required FR α expression level is ≥  50% of tumor staining at ≥  2+ intensity . A 
stratification cutoff of ≥  75% at ≥  2+ will also be implemented to evaluate anti- tumor activity 
of IMGN853 based on higher levels of FR α expression. 
Cycle 1 Day 1 should occur within 7 calendar days from randomization. 
2.3.4. Blinding  and the BIRC  
This is an open- label study. Treatment assignment will not be blinded . A BIRC  will be used 
to provide an independent assessment of radiographic tumor assessments. The BIRC will be 
blinded to the treatment assignment.   
The Sponsor has also decided to blind certain members of the study team to the efficacy 
endpoints. Specifically, clinical scientists, medical monitors, study statisticians, and study statistical programmers will not have access to the RECIST tumor assessments  for either  the 
Investigator ’s assessment captured in the EDC system or the BIRC data . Data managers and 
clinical trial managers will  have access to the tumor assessment data.  
Please see the Data Access  Plan  for this study for detailed information regarding the blinding 
of efficacy endpoints. 
2.3.4.1. BIRC 
Copies of all imaging scans must be obtained and sent to a central imaging vendor designated 
by ImmunoGen as outlined in the Imaging Manual. The central imaging ven dor will assess 
the quality of the images . The imaging vendor will be responsible for the formation and 
management of the BIRC .  
Tumor re sponse will be assessed by the Investigator and by the BIRC using RECIST 
Version  1.1. Response as determined by the Inv estigator  will be recorded in the electronic 
case report forms ( eCRFs ). The BIRC assessment will be used for the primary endpoint 
analysis.  
All time  points other than the Investigator- determined PD  will be assessed by BIRC in a non-
expedited manner. Resul ts of these assessments will not be communicated to the sites.  
For time  points with Investigator- determined PD , the BIRC will perform an expedited 
review . While the images are assessed by the BIRC, the patient should continue on the study 
treatment as planned if it is clinically acceptable  to do so. If the BIRC confirms PD , the 
patient must discontinue study treatment. If the BIRC does not confirm PD , the patient 
should continue receiving the study treatment unless there is a medical need (ie, rapid PD  or 
clinical deterioration) that requires an immediate change in therapy. Although disease 
progression may be determined by the Investigator  based upon clinical deterioration, every 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 20 of 62  
 effort should be made to document PD  using radiographic methods. The basis for 
determination of disease progression per clinical deterioration should be documented in the 
eCRFs.  
The central imaging vendor will ensure that the central radiologists remain blinded to the 
local assessment from the Investigator and other unblinding information. This and all other 
imaging procedures will be documented in an independent review charter agreed upon 
between ImmunoGen and the imaging vendor before initiation of any BIRC reviews. BIRC assessment of PD  will be used for the primary endpoint analysis.  
2.3.5. Assessment Schedule  
See protocol Appendix A , Appendix B , and Appendix C  for study schedules of assessments.  
2.4. Interventions  
2.4.1. Clinical Trial Material 
The dose levels  and dosing schedule is provided in Table 2 . 
Table 2: Dosing and Dosing Schedule for Phase 3 Portion 
Phase 3 (Randomization 2:1 ) 
Group  Drug  Dose  Dosing Schedule  
Arm 1  IMGN853  6 mg/kg AIBW Day 1 of a 3- week cycle  
Arm 2  Paclitaxel  80 mg/m2 Days 1, 8, 15, and 22 of a 4- week 
cycle  
PLD  40 mg/m2  Day 1 of a 4- week cycle  
Topotecan 
(4-week  cycle)  4 mg/m2 Days 1, 8, and 15 of a 4- week cycle  
Topotecan 
(3-week  cycle ) 1.25 mg/m2  Days 1 through 5 of a 3- week cycle  
AIBW = adjusted ideal body weight; PLD  = pegylated liposomal doxorubicin.  
The protocol provides additional details in S ection  4.1.2. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 21 of 62  
 3. GENERAL ANALYTICAL CONSIDERATIONS  
3.1. Data Sources  
Data are recorded on eCRFs . Central laboratory data will be provided via electronic data 
transfers . Section  12 of the protocol provides additional details regarding data recording and 
handling. Patient  entry into the eCRF system and randomization are completed through the 
Y Prime system. The data are then automatically mapped into the eCRF system , and will be 
available through the eCRF data extract.  
3.2. Definition of Baseline  
Study Day 1 (ie, Cycle 1 Day 1) will be designated as the first day a patient receives study 
drug. The baseline value is defined as the last non-missing value on or before the date of first 
dose of study drug.  
3.3. Missing Data  
Partial dates are allowed on the e CRF for adverse event (AE) onset and resolution dates, 
concomitant medication start and stop dates, and concomitant procedure, procedure dates. An 
entry for the year is required in the eCRF system for each of these dates . Only the month and 
day may be entered as unknown. Dates from these forms will be reported in listings as collected . Every effort will be made to query missing dates.  
For records with missing AE onset date, the following procedure will be employed for use in determining whether the AE is treatment emergent:  
• AE onset dates with missing day and non-missing month will be assumed to occur on the first day of the non-missing month, except for AEs occurring in the first month of dosing, in which case the date will be the first day of dosing. 
• AE onset dates with missing month will be assumed to occur on the first day of the non- missing year (ie , January 1), except for AEs occurring in the first year of 
dosing, in which case the date will be the first day of dosing.  
For records with a missing medication start and/or stop date, the following procedure will be employed for use in determining whether the medication is prior or concomitant: 
• Medication start dates with a missing day and non- missing month will be assumed 
to occur on the first  day of the non-missing month, except for medications 
occurring in the first month of dosing, i n which case the date will be the first day 
of dosing. 
• Medication start dates with missing month will be assumed to occur on the first 
day of the non-missing year (ie, January 1), except for medications occurring in the first year of dosing, in which case the date will be the first day of dosing.  
• Medications that are not ongoing and have a medication stop date with a missing day and non-missing month will be assumed to occur on the last  day of the non-
missing month. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 22 of 62  
 • Medications that are not ongoing and have a medication stop date with a missing 
month will be assumed to occur on the last  day of the non-missing year 
(ie, December 31).  
For records with a missing procedure date, the following procedure will be employed for use in determining whether the procedure is prior or concomitant: 
• Procedure dates with a missing day and non- missing month will be assumed to 
occur on the first day of the non-missing month, except for procedures occurring in the first month of dosing, in which case the date will be the first day of dosing. 
• Procedure dates with missing month will be assumed to occur on the first day of the non- missing year (ie , January 1), except for procedures occurring in the first 
year of dosing, in which case the date will be the first day of dosing.  
All o ther data will be reported as they are collected . No imputation methods will be used to 
replace missing data  unless otherwise stated in this document.  
3.4. Multiple Assessments for the Same Assessment Time Point  
In the case of multiple observations at a specif ic visit, the first non -missing measurement will 
be used for analysis, unless multiple study assessments are expected (eg, pre -dose vs post-
dose). When multiple study assessments are expected, the first non- missing measurement for 
the visit and assessment time point will be used for analysis.  
3.5. Multiple Study Centers  
No adjustment for study center is planned.  
3.6. Covariate Adjustment in Primary Analysis  
In the primary efficacy analysis, no c ovariate adjustment will be made. A stratified analysis 
using randomizat ion stratification factors will used for primary inference . The details are 
described in Section  5.2. 
3.7. Sample Size Reassessment  
Not applicable.  
3.8. Interim Analyses  
An interim futility analysis will be conducted when at least 80 PFS events as assessed by 
BIRC have occurred . The study will be terminated for futility at interim analysis if the 
observed hazard ratio [IMGN853 to IC c hemotherapy ] is greater than 1 in all randomized 
patients as well as in the FR α high-expression subgroup. No alpha spending is planned for 
this futility .  
Under the enrollment assumptions ( see Appendix 2: Monte-Carlo Simulation Report ), the 
interim analysis will occur when approximately 160 -180 patients have been randomized. 
This is expected to occur approximately 1 year after the first patient is randomized.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 23 of 62  
 The interim a nalysis of efficacy endpoints will follow the analysis methods described in the 
interim analysis plan .  
Additionally , there will be ongoing analysis of s afety data by the Independent Data 
Monitoring Committee ( IDMC ) as described in the IDMC charter .  
3.9. Timin g of Final Analysis 
If the study continues to a minimum of 333 patients for full enrollment (ie , the study is not 
stopped for futility at the interim analysis), the final analysis will be conducted when at least 
236 PFS events have been observed in the ITT population (as determined by the BIRC).  
3.10. Test Sizes  
Any tested hypotheses will be tested against 2-sided alternatives, using procedures that provide an expected probability of Type I error ( α) of 0.05. 
3.11. Hypothesis Testing and Multiple Comparisons  
3.11.1. Primary Endpoints  
The 2 null hypotheses for primary endpoints are: 
• H01: the survival function for PFS BIRC is the same between the IMGN853 arm and 
the IC chemo therapy  arm in the ITT population, and  
• H02: the survival function for PFS BIRC is the same between the IMGN853 arm and 
the IC chemo therapy  arm in the FR α high-expression subgroup.  
And the alternativ e hypotheses are:  
• Ha1: the survival function for PFS BIRC is different between  the IMGN853 arm and 
the IC chemo therapy  arm in the ITT population, and  
• Ha2: the survival function for PFS BIRC is different between  the IMGN853 arm and 
the IC chemo therapy  arm in  the FR α high-expression subgroup.  
The Hochberg procedure will be used to control the overall  type I error. Assume the log-rank 
p-values for the 2 primary endpoints are P (1) and P (2) (P(1) ≤ P(2)). Let H 0(1) be the null 
hypothesis corresponding to P (1) and H 0(2) the hypothesis corresponding to P(2). The 
Hochberg will first test P (2) against 0.05.  
• If P (2) ≤ 0.05 , then reject both H 01 and H 02 and claim statistical significance in both 
endpoints.  
• If P (2) > 0.05, then P (1) will be tested against 0.025.  
− If P (1) ≤ 0.025, then reject H 0(1) and claim statistical significance for that 
endpoint.  
− If P (1) > 0.025, then no null hypothesis will be rejected.  
This Hochberg procedure is illustrated in Figure 3.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 24 of 62  
 Figure 3: Hochberg Procedure  
P(2)  ≤ 0.05 
No Null hypothesis 
is rejectedReject H 0(1)STOP
& 
 reject both H 01 & H 02 
NOYES
P(1)  ≤ 0.025NO
YES
 
3.11.2. Key Secondary Endpoints  
For the 3 key secondary endpoints, a hierarchical testing procedure will be applied to control 
the overall type I error only if both null hypotheses for the primary endpoints are rejected using the Hochberg method. The order of the hierarchical testing is as follows: 
• ORR
BIRC 
• OS 
• Primary PRO  endpoint as described in Protocol S ection  11.7 ( primary endpoint 
for quality of life [ QoLP ]) 
The null hypothesis for ORR BIRC is as follows: 
• H03: the ORR BIRC is the same between the IMGN853 arm and the IC 
chemotherapy  arm in the ITT population.  
And the alternative hypothesis is as follows: 
• Ha3: the ORR BIRC is different between IMGN853 arm and the IC chemo therapy 
arm in the ITT population.  
The null hypothesis for OS is as follows: 
• H04: the survival function for OS is the same between the IMGN853 arm and the 
IC chemotherapy  arm in the ITT population.  
And the alternative hypothesis is as follows: 
• Ha4: the survival function for OS is different between the IMGN853 arm and the 
IC chemothearpy  arm in the ITT population.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 25 of 62  
 The null hypothesis for QoLP is as follows: 
• H05: the QoLP is the same between the IMGN853 arm and the IC chemo therapy 
arm in the ITT population.  
And the alternative hypothesis is as follows: 
• Ha5: the QoLP is different between the IMGN853 arm and the IC chemo therapy 
arm in the ITT population.  
This procedure first tests H 03 at a 2-sided alpha level of 0.05. If H 03 is rejected favoring the 
IMGN853 arm, statistical significance will be claimed for O RR BIRC, and H 04 will be tested at 
a 2-sided alpha level of 0.05. If H 04 is rejected favoring the IMGN853 arm, statistical 
significance will be claimed for OS , and H 05 will be tested at a 2-sided alpha level of 0.05. 
The procedure will stop at the first test not significant at a 2-side alpha level of 0.05 and no 
claims will be made for that endpoint and subsequent endpoints. 
3.12. Analysis Populations  
Five analysis populations will be defined for use with various analyses. Table 3  illustrates the 
relationship between each population and the analyses for which the data from the population will be used. 
Table 3: Analysis Populations 
Analysis 
Popul ation  Analysis  
Baseline  Patient Disposition  Efficacy  Safety  
Screened  X    
ITT X X X  
Per Protocol    X  
Response Evaluable    ORR only   
CA-125 Evaluable    CA-125 only   
Safety     X 
CA-125 = cancer intigen 125; ITT  = intent- to-treat; ORR  = objective response rate.  
3.12.1. Screened  
The Screened population includes all patients entered into the eCRF system who have signed 
an informed consent.  
3.12.2. ITT Population 
The ITT population is defined as all patients randomized  in the Phase 3 portion of the study 
(Amendment 6 and onwards).  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 26 of 62  
 3.12.3. Per Protocol Population 
Per Protocol Population is defined as all patients  randomized in the Phase 3 portion of the 
study who have received at least 1 dose of the study drug, excluding patients with protocol 
deviations in the following categories: patients  - 
• whose tumors have FRα low expression ( <50% tumor staining at ≥  2+ intensity ), 
and/or  
• who have received  four (4) or more prior lines of cancer therapy, and/or  
• who are not secondary platinum resistan t.  
3.12.4. Response -Evaluable Population 
The Response-Evaluable population is defined as all patients randomized in the Phase 3 portion of study who have received at least 1 dose of study drug, undergone baseline and at least 1 post- baseline tumor assessment , or who died within 105 days of randomization.  
3.12.5. CA-125-Evaluable Population 
The CA -125-Evaluable population is defined as all patients randomized in the Phase 3 
portion of the study whose pre treatment sample is  ≥ 2.0 times the upper limit of normal 
(ULN) , within 2 weeks prior to randomization, and who have at least 1 post- baseline CA -125 
evaluation .  
3.12.6. Safety Population 
All enrolled patients  who received at least 1 dose of IMGN853 or IC chemotherapy  will be 
included in the Safety population. 
 
3.13. Data Display Characteristics  
Data displays produced for this study will include summary tables, data listings, and figures. 
Data listings will be produced for all recorded data as described in Secti on 4, Section  5, 
Section  6, and Section  8.  Summary tables will be produced as specified in Section  4, 
Section  5, Section  6, and  Section  8. Additional data listings will be produced for outcome 
measures that involve extensive procedures to derive the analyzed outcomes. Figures will be 
produced when specified in Section  4, Section  5, and  Section  6. 
Stage 1 data will be provided in listings only. As there are only 4 patients  in Stage 1, no 
tables or figures will be provided. T ables , listings , and figures will be provided for the 
Phase 3 portion of the study. Stage 1 and Phase 3  data will be presented separately.  
Data listings will report the data recorded on the eCRF or derived for each patient . Data will 
be ordered by treatment,  patient  number, and date/time of assessment . When expedient, 
additional levels of ordering hierarchy may reflect subsets of assessments within patient . 
Data listings will not display patient  initials.  
Summary tables will display summary statistics calculated for each of the treatment groups, unless described otherwise in Section  4, Section  
 5, and  Section  6, and Section  8. For s afety 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 27 of 62  
 analyses, the columns of the summary tables will be IMGN853  6mg/kg Q3W, P ac, PLD, 
Topo Q3W or Q4W , and Total Investigator ’s Choice. For efficacy analyses, the columns of 
the summary tables will be Arm  1: IMGN853 6mg/kg Q3W and Arm 2: Investigator ’s 
Choice.  
The summary statistics displayed will be a function of the type of data associated with the 
summarized assessment . Unless stated otherwise in relevant sections, Section  4, Section  5, 
and Section  6, continuous data will be summarized with the number of non-missing values, 
mean, standard deviation, minimum, median, and maximum. Categorical data will be summarized with the number of non-missing values and the numbers of values equal to each of the possible values. Percentages of patients  with each of the possible values will be 
calculated from the number of patients  in the corresponding analysis population, unless 
stated otherwise . Some continuous variables may also be grouped into categorical levels and 
evaluated in frequency tables.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 28 of 62  
 4. PATIENT  ACCOUNTABILITY  
4.1. Patient  Characteristics  
Patient  characteristics will be summarized and listed for the ITT population by the treatment 
to which they were randomized (planned treatment). For Stage 1, listings of the following 
information will be provided for the Safety population by the treatment actually received 
(actual treatment).  
If the primary efficacy endpoint (PFS BIRC) is only statistically significant in patients with 
FRα high expression but not in the ITT, the following subgroup tables will be prepared for 
patients with  FRα high expression.   
• Demographics  and baseline disease characteristics  
• Prior cancer therapy  
4.1.1. Demography 
Data collected about the following patient  characteristics at the screening  visit will be 
summarized  as follows: 
• Age is collected in the Y  Prime system at the time of patient registration . As this 
is a global study, there are certain regions where local regulations prohibit the 
collection of a complete date of birth . Therefore, age will not be recalculated for 
analysis purposes. The collected age will be used for summarization.  
• Sex and childbearing potential yes/no 
• Ethnicity  
• Race  
All demography data, including informed consent date, will be listed.  
4.1.2. Height  and Baseline Weight , AIBW , and Body Surface Area  
Height and  baseline weight , AIBW , and body surface area ( BSA ) will be summarized by 
treatment group and presented in a listing. Note that AIBW and BSA are collected depending 
on the treatment group to which a patient is assigned . Thus, baseline AIBW and BSA will 
only be summarized for the treatment groups for which this data is available. 
4.1.3. Medical History  
Medical history will be coded using Medical Dictionary for Regulatory Affairs ( MedDRA ) 
(Version 18.1 or later), associating lower- level terms with preferred terms (PTs) and system 
organ classes  (SOCs) by the primary hierarchy. Medical histories will be summarized as the 
number and percentage of patients  who reported at least 1 medical history event ; and  number 
and percentage of patients  who reported at least 1 medical history event in each SOC . Within 
each SOC , tables will display the number and percentage of patients  reporting at least 
1 medical history event as designated by PT . All medical history information will also be 
listed.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 29 of 62  
 4.1.4. Disease Characteristics , Prior Therapy , and Gene Mutations  
Listing s of all collected data related to disease characteristics and prior therapy will be 
provided. A summary of the following elements will also be provided:  
• Primary diagnosis (epithelial ovarian  cancer , fallopian tube cancer , primary 
peritoneal  cancer , other). 
• FRα status  
• Histology 
• Disease s tage at initial diagnosis  
• Histologic grade 
• Prior radiotherapy (yes/no) 
• Prior systemic therapy  
− The number of prior systemic therapies is defined as the number of distinct 
treatment regimens  
 Adjuvant ± Neoadjuvant will be considered 1 regimen  
 Maintenance therapy will be considered part of the preceding regimen  
 PARP inhibitor therapy will be considere d a prior treatment  unless 
given as maintenance therapy 
 Hormonal therapy will not be considered prior systemic treatment (included 
in this category are tamoxifen, anastrozole, exemestane, megasterol , and 
letrozole)  
• Prior surgery (yes/no) 
• Prior exposure to bevacizumab (yes/no) 
• Any BRCA mutations mutations (yes[ BRCA1, BRCA2 ]/no) 
4.2. Patient Disposition  
4.2.1. Screened and Enrolled Patients   
The number and percentage of patients who were s creened and enrolled (r andomized) will be 
summarized by overall, geographic region (North America and Europe), country, and site.   
4.2.2. ITT, Safety Disposition  
A summary of patient disposition will summarize, for the ITT population, the number of 
patients  randomized  and the reason for treatment and study discontinuation. This summary 
will also be produced for the Safety population if more than 5% of patients  in the ITT 
population are excluded from the Safety population. 
Percentage of patients who withdrew for each reason on the End-of- Treatment and 
End-of-Study forms will be calculated using all members of the relevant population in the 
relevant treatment group for the denominator. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 30 of 62  
 A listing of End-of-Treatment and End-of-Study information will be provided for the ITT 
population. For Stage 1, a listing of End-of- Treatment and End -of-Study information will be 
provided for the Safety population. 
A hierarchical table of the populations in  which s creened patients were included wi ll 
summarize the relationship to  the analysis populations. The number of screened patients will 
be provided in the Total column. Given population definitions, the ITT population will be 
treated as the starting, parent population. The number and percentage of ITT patients 
included in the Safety population and Per -protocol population will be presented for each 
treatment group. This table will be produced for all patients at all sites, pooled.  
4.2.3. Protocol Deviations and Population Inclusions  
Protocol deviations will be captured in a protocol deviation log. A summary of the number of patients with any protocol deviation will be provided by treatment group for the ITT 
population.  
Protocol deviations will also be summarized  by the following categories, as collected in the 
protocol deviation log: 
• Those who entered the study even though they did not satisfy the entry criteria. 
• Those who developed withdrawal criteria during the study but were not 
withdrawn . 
• Those who received the wrong treatment or incorrect dose. 
• Those who received an excluded concomitant treatment. 
The summary will be grouped first by deviation categories and then by site within each deviation category. 
A listing from the protocol deviation log will be provided, grouped by site for the ITT 
population. The Stage 1 listing will use the Safety population. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 31 of 62  
 5. EFFICACY ANALYSES  
The main efficacy analyses will use data from the ITT population. Patients  will be analyzed 
by the treatment to which they were randomized (pl anned treatment) .  
5.1. Efficacy Outcomes  
5.1.1. Best Overall Response  
Best overall response (BOR)  for a patient is the best response designation (as assessed by 
either the BIRC or the Investigator, depending on the analysis) recorded between the date of 
randomization and the date of objectively documented PD  per RECIST Version  1.1, the date 
of the start of new anti- cancer therapy , or the date of study discontinuation, whichever occurs 
first. When an analysis cutoff date is implemented, only radiological assessments occurring 
on or prior to the cutoff date will be used for analysis.  Patients with an overall response of 
CR or PR must have a repeat tumor assessment performed no less than 4 weeks (28 days) 
after the criteria for response are first met . When  stable disease is the best overall response, it 
must meet the  minimum duration of 35 days (6 weeks – 1 week window = 35 days from the 
date of randomisation). The confirmatory scan is valid following treatment discontinuation as long as the patient has not started a new anti- cancer therapy.   
5.1.2. CA-125 Response 
A CA- 125 response is defined as a ≥  50% reduction in CA-125 levels from baseline. The 
response must be confirmed and maintained for at least 28 days. The CA -125 response will 
be conducted using the CA-125-Evaluable population. The date of response corresponds to the date when the CA -125 level is first reduced by 50%. The summary table for CA-125 will 
include the number ( percentage) of patients in the CA-125-Evaluable population, and that 
sample size will then be used as the denominator for CA-125 response rate. 
5.1.3. DOR 
DOR is defined as the time from the date of the first response (CR or PR), whichever occurs 
first, to the date of PD or death from any cause, whichever occurs first . DOR  is only defined 
for patients who have a best overall response of CR or PR.  
Per the BOR definition, patients with an overall response of CR or PR must have a repeat 
tumor assessment performed no less than 4 weeks after the criteria for response are first met . 
The first date at which a CR or PR response was noted will be used to calculate DOR, not the 
date of the confirmatory tumor assessment. 
Patients who started a new anti -cancer therapy prior to documented  PD or death will be 
censored at the last radiological assessment prior to initiation of new anti- cancer therapy . 
Patients who did not have PD or death will be censored at the date of their last radiological 
assessment . Patients who had PD or death after missing 2 or more consecutive radiological 
assessments (PD or death date - last radiological assessment date +1 ≥  105 days) will be 
censored at the date of their last radiological assessment . When an analysis cutoff date is 
implemented, only data (deaths or radiological assessments) occurring on or before the cutoff 
date will be used for analysis. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 32 of 62  
 5.1.4. ORR 
The ORR will be calculated as the number of patients  with a BOR of CR or PR divided by 
the number of patients  in the ITT population. Patients  without at least 1 post- baseline 
RECIST assessment will be treated as non -responders ( ie, these patients will contribute to the 
denominator, but not the numerator). 
5.1.5. OS 
OS is defined as the time from the date of randomization until the date of death from any 
cause.  
Patients who are alive or lost to follow -up at the analysis are censored at the last known date 
at which they were known to be alive. When an analysis cutoff date is implemented, only 
deaths occurring on or before  the cutoff date are counted as OS events . Patients whose date 
of death or the last date at which the patient was known to be alive ( eg, after the data cutoff 
date) will be censored at the analysis cutoff date.  
5.1.6. PFS 
PFS is defined as the time from the date of randomization  until the date of PD or death from 
any cause, whichever occurs first. PFS is defined based on radiological assessments and 
determined by the BIRC or the Investigator (depending on the analysis). Clinical progression 
is not considered a progression endpoint.  
 
Table 4 summar izes the rules to be used for PFS. When an analysis cutoff date is 
implemented, only data (deaths and radiological assessments) occurring on or prior to the 
cutoff date will be used for analysis.  
 
Table 4: PFS Definitionsa  
Situation  Date of PFS Event or Censoring  Outcome 
No baseline tumor assessments 
or post- baseline radiological 
assessments, and patient did not die within 105 days of 
randomization  Date of randomization  Censored  
No baseline tumor assessments 
or post- baseline radiological 
assessments, and patient died 
within 105 days of 
randomization  Date of death  Death  
Death  Date of death  Death  
Radiological Progression Date of first radiological 
assessment  indicating progression 
(ie, OR  = PD ). Progression 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 33 of 62  
 Situation  Date of PFS Event or Censoring  Outcome 
New anti -cancer therapy  prior 
to PD or death (including 
palliative radiotherapy during study treatment)  Date of last radiological  
assessment prior to the start of the 
new anticancer therapy  Censored  
No death or PD  Date of last radiological 
assessment  Censored  
PD or death after missing 2 or 
more consecutive radiological 
assessments (PD or death date 
- last radiological assessment 
date +1 ≥  105 days) Date of last adequate radiological 
assessment  showing no PD  Censored  
a Includes radiographic progression only - PFS BIRC is based on BIRC assessment; PFS INV is based on the 
Investigator ’s assessment . 
OR = overall response; PD  = disease progression; PFS  = progression- free survival.  
5.1.7. RECIST -Related Endpoints – BIRC or Investigator ’s Assessment  
The primary analyses will use en dpoints based on the BIRC assessment of response. The 
Investigator assessment of response will be used for sensitivity analyses. A subscript of 
BIRC or INV (Investigator ) will indicate which assessment of response is used for the 
calculation of the endpoint. For example, BOR BIRC and PFS BIRC will be used to denote BOR 
and PFS based on the BIRC assessment of response. BOR INV and PFS INV will be used to 
denote the BOR and PFS based on the Investigator ’s assessment of response.  
5.1.8. Time to Response 
Time to response ( TTR ) is defined as the time from the date of randomization until the date 
of the first observed CR or PR. TTR is only defined for patients  who have confirmed CR or 
PR. 
5.1.9. PFS2  
PFS2 is defined as time from randomization to second PD or death. Specifically, for the purposes of the PFS2 analysis, the date of event was defined as the following, whichever occurred first:  
• Date the patient experienced an event of radiological or clinical progression reported on the long- term follow -up form.  
• Date of  death .  
• Date of end of next- line treatment .  
− For next-line treatment, any therapy other than radiotherapy will be  
considered.  
• Any event of PD  reported during the long- term follow -up evaluation will be  
considered, including PD  in patients who did not receive subsequent next- line 
treatment.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 34 of 62  
 • Patients who did not experience PD  (BIRC) during the study period but who had 
PD documented on the follow-up form w ill also be considered as having an event 
of PFS2.  
− For patients who did not receive subsequent therapy, nor experience PD  or 
death during long- term follow -up, the data w ill be  censored at the time of the 
last follow -up contact.  
− Data from patients lost to follow -up after at least 1 follow- up assessment w ill 
be included in the analysis as censored observations on the date the patient 
was last known to be alive.  
− Patients who did not have follow-up contacts w ill be  censored on the date of 
study discontinuation. 
5.2. Primary Efficacy Outcome Analysis 
The protocol specifies the following primary efficacy endpoint: 
• PFS as assessed by the BIRC  
− In all patients randomized on the study (ie , PFS BIRC,All ) 
− In patients with high FR α level (≥  75% of tumor staining at ≥  2+ intensity) 
(ie, PFS BIRC,High ). 
The distribution of PFS BIRC,All  and PFS BIRC,High  will be summarized using the Kaplan- Meier 
method. PFS rates will be reported at 3 -month intervals (eg, 3 months, 6 months, etc.). 
Median times will be estimated for each treatment from the 50th percentile of the 
corresponding Kaplan- Meier estimates . 95% c onfidence intervals (CI) for the 3-month 
intervals and median times will also be provided . The primary comparison between 
treatments will use the log -rank test stratified by the randomization stratification factors . 
Stratified analysis using values collected on the eCRFs  will be conducted as sensitivity 
analysis . As a sensitivity analysis, the results from an unstratified analysis will also be 
provided. The chi -square p -values from the log-rank tests will be reported. 
Additionally, the restricted mean survi val time (RMST) for PFS BIRC,All  and PF SBIRC,High  will 
also be reported at 3 month intervals (eg, 3 months, 6 months, etc.). The RMST will be 
compared between treatments stratified by the randomization stratification factors  (Zucker 
DM 1998). As a sensitivity analysis, the RMST from an unstratified analysis will also be 
provided. Stratified analysis using values collected on the eCRFs  will be conducted as 
sensitivity analysis.  
For PFS BIRC,All , the strata will be FR α expression level (high vs medium), IC chemotherapy 
(Pac vs PLD vs Topo), and the number of prior lines of therapy (1 or 2 vs 3). For 
PFSBIRC,High , the strata will be IC chemotherapy (Pac vs PLD vs Topo), and the number of 
prior lines of therapy (1 or 2 vs 3). 
The hazard ratio for PFS BIRC,All  and PFS BIRC,High  treatment comparisons will be estimated 
using a stratified Cox proportional hazards model. As a sensitivity analysis, the hazard ratio 
from an unstratified Cox proportional hazards model will also be provided. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 35 of 62  
 The hazard ratio (IM GN853 arm vs IC chemotherapy arm) will be reported using the 
maximum likelihood estimate along with 95% CI . The IC chemotherapy arm will be used as 
the reference treatment (ie, denominator of the hazard ratio). A time -to-event hazard ratio 
less than 1.0 would indicate an IMGN853 benefit over IC chemotherapy. 
Kaplan -Meier estimates of PFS and RMST  for PFS at 3, 6, 9, and 12 months will also be 
compared between the IMGN853 and IC chemotherapy arms. 
As a sensitivity analysis, PFS BIRC will also be analyzed in the Per -protocol population.  
Patients will be analyzed by the actual treatment they received.  
For diagnostic purposes, the proportional hazard assumption will be checked using 
appropriate approaches; including comparing the hazar d ratios from stratified and unstratified 
Cox models, as well as checking graphs (ie, Kaplan -Meier plots: plot of ln( -ln(s(time))) vs 
time or ln(time), and plots of Scheonfeld residuals vs time). A summary of these checks will be provided to the Sponsor. 
5.3. Secondary Efficacy Analyses  
The protocol describes the following key secondary efficacy endpoints: 
• ORR per RECIST Version  1.1 criteria based on the BIRC assessment  (ORR BIRC). 
• OS. 
• Primary PRO endpoint as described in the PRO  analysis appendix. 
Additionally, the following efficacy endpoints will also be analyzed: 
• PFS as assessed by the Investigator (PFS INV). 
• ORR per RECIST Version  1.1 as assessed by the Investigator (ORR INV). 
• DOR based on BIRC assessment (DOR BIRC). 
• DOR based on Investigator ’s assessment (DOR INV). 
• GCIG CA -125 criteria clinical response rate. 
• TTR  based on BIRC assessment (TTR BIRC). 
• TTR based on Investigator ’s assessment (TTR INV). 
Unless noted otherwise, all analyses of secondary endpoints will be based on the ITT 
population. In addition, ORR will also be summarized using the R esponse-E valuable 
population. 
As a sensitivity analysis, ORR BIRC and OS will also be summarized on the Per-protocol 
population. 
GCIG CA -125 response will be summarized using the CA -125 Response-E valuable 
population only. 
DOR will be summarized in patients with confirmed CR or PR only.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 36 of 62  
 ORR  and GCIG CA -125 response will be analyzed using a Cochran- Mantel -Haenszel 
(CMH) test stratifie d by the randomization stratification factors to test for differences 
between the IMGN853 arm and the IC chemotherapy arm . P-value and 95% CIs  for the 
proportion of patients  with ORR or GCIG CA -125 clinical response will be provided.  
The distribution of t ime-to-event variables (PFS, DOR, and OS) will be summarized using 
the Kaplan -Meier method . PFS, DOR, and OS will be reported at 3 month intervals (eg, 
3 months, 6 months, etc.). Median times will be estimated for each treatment from the 50th 
percentile of  the corresponding Kaplan- Meier estimates . 95% CI s for the 3-month intervals 
and median times will also be provided . The primary comparison between treatments will use 
the log- rank test stratified by the randomization stratification factors . Stratified ana lysis using 
values collected on the eCRFs will be conducted as sensitivity analysis. As a sensitivity 
analysis, the results from an unstratified analysis will also be provided. The chi -square p -
values from the log-rank tests will be reported.  
The hazard ratio for the time- to-event variables ( PFS, DOR, and OS) treatment comparisons 
will be estimated using a stratified Cox proportional hazards model. As a sensitivity analysis, 
the hazard ratio from an unstratified Cox proportional hazards model will also be provided. 
The hazard ratio (IMGN853 arm vs IC chemotherapy  arm) will be reported using the 
maximum likelihood estimate along with 95% CI . The IC chemotherapy arm will be used as 
the reference treatment (ie, denominator of the hazard ratio). A time -to-event hazard ratio 
less than 1.0 would indicate an IMGN853 benefit over IC chemotherapy. For diagnostic purposes, the proportional hazard assumption will be checked using 
appropriate approaches; including comparing the hazard ratios from stratified and unstratified 
Cox models, as well as checking graphs (ie, Kaplan -Meier plots: plot of ln( -ln(s(time))) vs 
time or ln(time), and plots of Scheonfeld residuals vs time). A summary of these checks will 
be provided to the Sponsor. 
TTR will be summarized using descriptive statistics  for patients who achieved a confirmed 
response of CR or PR as assessed by BIRC or the Investigator (TTR
BIRC and TTR INV).  
The analysis of the primary PRO  endpoint will be described in a separate document  to the 
SAP.   
The median follow up time and its 95% CI  will be estimated using reverse Kaplan -Meier  
method on OS. 
5.4. Exploratory Efficacy Analyses  
The protocol describes the following exploratory efficacy analyses: 
• Evaluate association of BRCA mutation status and FR α expression level with 
anti-tumor activity of IMGN853.  
• Evaluate the association of anti -tumor activity and/or safety with the following:  
− Mutational status and  other genomic alterations in tumor samples .  
− Activation status of oncogenic pathways in tumor samples .  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 37 of 62  
 − Expression and polymorphism of drug transporters such as MDR1 (ie, PgP) 
and other proteins that may influence anti- tumor activity or safety .  
− Soluble FR α level in blood samples. 
− Genotyping of FcγR .  
• Evaluate PFS2 . PFS2 analysis will be conducted using the same method as in PFS 
analysis.  
5.5. Efficacy Analysis on Subgroups of Patients 
PFS BIRC, PFS INV, ORR BIRC, ORR INV, and OS  will be analyzed with the following subgroups 
of patients : 
• BRCA status (positive vs negative/unknown).  
• FRα levels (≥  75% tumor staining at ≥  2+ intensity vs < 75% tumor staining at 
≥ 2+ intensity). 
• Age (< 65 year vs ≥  65 years) . 
• Baseline Eastern Cooperative Oncology Group Performance State ( ECOG PS) 
(0 vs 1). 
• Prior exposure to bevacizumab (yes vs no). 
• Number of prior lines of therapy ( 1 or 2 vs 3). 
• Type of IC chemotherapy . 
• Location of metastasis (visceral vs non -visceral) . 
• Race (white vs non -white) . 
The summaries for time to event  variables  include the number and percentage of events, 
median and its 95% CI , 2-sided P- value, and hazard ratio (IMGN853 to IC chemo) and its 
95% CI . 
The forest plot of time to event  variables will display the number of subjects, events, hazard 
ratio (IMGN853 to IC chemo) and its 95% CI .   
The summaries for ORR  include the ORR  and its 95% CI , and difference in ORR  (IMGN853 
– IC chemo)  and its 95% CI. 
The forest plot of ORR will display the number of subjects, difference in ORR (IMGN853 – IC chemo) and its 95% CI .   
5.6. Additional Sensitivity Analyses  
As additional sensitivity analy ses, PFS BIRC,All  will also be analyzed by:  
• Stratifying only by FR α level . 
• Stratifying by FR α level, and using the number of prior therapies and IC 
chemotherapy as covariates . 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 38 of 62  
 As additional sensitivity analyses, PFS BIRC,High  will also be analyzed by: 
• Using the number of prior therapies and IC chemotherapy as covariates. 
The primary analyses for PFS are based on the BIRC  assessment  of radiological assessments 
only. A sensitivity analysis of PFS based on the Investigator assessment (PFS INV) is 
described Section  5.3  As an additional sensitivity analysis, PFS will be re-assessed by using 
the Investigator ’s radiological and clinical assessments  (PFS AINV). In this analysis, PFSA INV 
will be defined as the time from the date of the randomization  until the date of PD by 
radiological or clinical assessment or death from  any cause, whichever occurs first , as 
determined by the Investigator. If PD is noted in both clinical and radiological assessments, 
the first date where PD is noted will be used for analysis.   
Table 5: PFSA INV Definitionsa  
Situation  Date of PFS Event or Censoring  Outcome 
No baseline tumor assessments 
or post- baseline tumor 
assessments, and patient did 
not die within 105 days of 
randomization and no clinical progression noted Date of randomization  Censored  
No baseline tumor assessments 
or post- baseline tumor 
assessments, and patient died within 105 days of 
randomization and no clinical progression noted Date of death  Death  
Death  Date of death  Death  
Radiological or c linical 
progression The earliest of:  
Date of first radiological 
assessment indicating progression (ie, OR  = PD  on RECIST 
response eCRF), or  
Date of first instance of clinical 
progression (ie , on RECIST 
response eCRF, the earliest date 
of clinical progression). Progression 
New anti -cancer therapy prior 
to progression or death 
(including palliative radiotherapy during study 
treatment)  Date of last radiological 
assessment prior to the start of the new anticancer therapy  Censored  
No death or progression Date of last radiological 
assessment  Censored  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 39 of 62  
 a Includes Investigator  assessed radiological and clinical progression . 
eCRF  = electronic case report form; OR  = overall response; PD  = disease progression; PFS  = progression- free 
survival; RECIST  = Response Evaluation Criteria in Solid Tumors.  
 
Additionally, f or PFS BIRC, rather than censoring patients who progressed or died after 
missing 2 or more consecutive radiological assessments , the date of the PFS event will be 
backdated to the date of first missed assessment. Th is analysis will be called PFS BBIRC. 
Table 6 provides the rules for PFSB BIRC. 
Table 6: PFSB BIRC Definitionsa  
Situation  Date of PFS Event or Censoring  Outcome 
No baseline tumor assessments 
or post- baseline radiological 
assessments, and patient did not die within 105 days of 
randomization  Date of randomization  Censored  
No baseline tumor assessments 
or post- baseline radiological 
assessments, and patient died within 105 days of 
randomization  Date of death  Death  
Death  Date of death  Death  
Progression Date of first radiological 
assessment indicating progression 
(ie, OR  = PD ). Progression 
New anti -cancer therapy prior 
to PD or death (including 
palliative radiotherapy during 
study treatment)  Date of last radiological 
assessment prior to the start  of 
the new anticancer therapy  Censored  
No death or progression Date of last radiological 
assessment  Censored  
PD or death after missing 2 or 
more consecutive radiological 
assessments (PD or death date 
- last radiological assessment date +1 ≥  105 days). Date of first missed radiological assessment (ie, date of the last 
adequate ass essment + 42 days 
[ie, 6 weeks]) . Progression 
a Includes BIRC assessed radiographic progression only. Progression (radiological or 
clinical) or death after missing 
2 or more consecutive 
radiological assessments  
(PD or death date - last 
radiological assessment 
date + 1 ≥ 105 days)  Date of last RECIST assessment  Censored  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 40 of 62  
 OR = overall response; PD  = disease progression; PFS  = progression- free survival.  
Additionally, PFSR BIRC will be analyzed by not censoring patients receiving palliative 
radiotherapy during study treatment while everything else is identical to PFS BIRC. Table 7  
provides the rules for PFSR BIRC.  
Table 7: PFSR BIRC Definitionsa  
Situation  Date of PFS Event or Censoring  Outcome 
No baseline tumor assessments 
or post- baseline radiological 
assessments, and patient did not die within 105 days of randomization  Date of randomization  Censored  
No baseline tumor assessments 
or post- baseline radiological 
assessments, and patient died within 105 days of 
randomization  Date of death  Death  
Death  Date of death  Death  
Radiological progression  Date of first radiological 
assessment indicating progression 
(ie, OR  = PD ) Progression 
New anti -cancer therapy prior 
to PD or death ( not including 
palliative radiotherapy during 
study treatment)  Date of last radiological assessment prior to the start of the new anticancer therapy  Censored  
No death or progression Date of last radiological assessment  Censored  
PD or death after missing 2 or 
more consecutive radiological 
assessments (PD or death date 
- last radiological assessment 
date +  1 ≥ 105 days)  Date of last adequate radiological assessment showing no PD Censored  
a Includes radiographic progression only. 
OR = overall response; PD  = progressive disease or disease progression; PFS  = progression- free survival.  
 
The following sensitivity analyses will also be performed: 
• The concordance/discordance rate between the PFS outcomes for the B IRC 
assessment and the INV assessment will be summarized.  
• The concordance/discordance rate between the BIRC Best Overall Response and 
the INV Best Overall Response will be summarized.  
• In cases where the BIRC and INV assessment are different, PFS will be re -
calculated using several methods of censoring: 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 41 of 62  
 − Method 1 (PFS C): INV PFS of patients with at least 1 scan submitted for 
BIRC review .  
 The rules for PFS C are the same as those described in Table 4   
 except  only patients with at least 1 scan submitted for B IRC review are 
included in the analysis.  
− Method 2 (PFS D): If PFS BIRC was censored but PFS INV had an event, replace 
PFS BIRC with PFS INV.  
 Table 4  describes the rules for PFS BIRC and PFS INV.  
 PFS BIRC and PFS INV will be calculated prior to calculating PFS D.   
 PFSD will be equal to PFS BIRC except in cases where PFS BIRC is censored, but 
PFS INV shows an event . In those cases , PFS4  will be equal to PFS INV. 
− Method 3 (PFS E): If both PFS BIRC and PFS INV had an event, but the INV date 
is earlier than the BIRC  date, replace BIRC  PFS date with INV PFS date.  
 Table 4   describes the rules for PFS BIRC and PFS INV.  
 PFS BIRC and PFS INV will be calculated prior to calculating PFS E. 
 PFSE will be equal to PFS BIRC except in cases where PFS BIRC and PFS INV both 
indicate an event and the PFS INV event date is earlier than the PFS BIRC event 
date . In those cases, PFS E will be equal to PFS INV. 
5.7. Strategies for Pooling Stratification Factors  
This study uses 3 factors to stratify patients  for randomization, with a total of 12 stratification 
levels . At the final analysis , levels may have a small number of patients  in 1 or more of the 
stratification levels . The following strategy for pooling stratification levels will be used if  1 
or more of the stratification  levels contains fewer than 12 patients  (Table 8 )  
After pooling, each stratum is expected to have at least 1 event at the final analysis.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 42 of 62  
 Table 8: Pooling of Stratification Factors 
FRα Priors IC C hemo therapy  If n < 12 P ool W ith 
high 1,2 PLD  Next stratum  
high 1,2 Pac Previous stratum  
high 1,2 Topo Previous stratum  
high 3 PLD  Next stratum  
high 3 Pac Previous stratum  
high 3 Topo Previous stratum  
medium  1,2 PLD  Next stratum  
medium  1,2 Pac Previous stratum  
medium  1,2 Topo Previous stratum  
medium  3 PLD  Next stratum  
medium  3 Pac Previous stratum  
medium  3 Topo Previous stratum  
FRα = folate receptor alpha; IC  = Investigator ’s choice; Pac  = paclitaxel; PLD  = pegylated liposomal 
doxorubicin; Topo  = topotecan.  
5.7.1. Rationale for pooling approach  
The FR α levels will not be pooled , and the number of prior lines of therapy is an important 
prognostic indicator. Therefore, the approach above is to pool patients  by the type of IC 
chemotherapy in consideration prior to randomization. 
5.8. Prognostic and Predictive Value of FRα  Expression on PFS BIRC 
Prognostic value of FR α expression on PFS BIRC will be analyzed for patients in the IC chemo 
arm.  Hazard ratio ( FRα high to FR α medium) and its 95% CI will be reported. 
Predictive value of FRα expression on PFS BIRC will be analyzed for the ITT population using 
a Cox proportional hazard regression model with treatment, FR α expression, and their 
interaction as covariates.  The hazard ratio (IMGN853 to IC chemo) will be reported for  
patients with FR α high expression and FR α medium expression separately.  The interaction 
hazard ratio and its 95% CI will also be reported.  The null hypothesis that the hazard ratio (IMGN853 to IC chemo) is the same between patients with FR α high expression and patients 
with FR α medium expression will be tested using the interaction term.  
5.9. Other Efficacy -related Summaries 
New  anti-cancer therapy data will be summarized for the ITT population by randomized arm 
as follows: 
• Number and percent age of patients receiving new anti- cancer therapy . 
• Type of new anti- cancer therapy . 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 43 of 62  
 Listings of efficacy -related data for will include  the f ollowing: 
• All lesion assessments (target lesion, non -target lesion, new lesion). 
• New anti -cancer therapy . 
• BIRC RECIST assessments . 
• Investigator ’s RECIST assessments. 
• CA-125 results. 
• Derived parameters for CA -125 response, BOR, PFS, DOR, TTR, and OS. 
• Censor ing for time -to-event variables . 
Listings of efficacy -related data for Stage 1 will be presented using the Safety population and 
actual treatment received , as follows: 
• All lesion assessments (target lesion, non -target lesion, new lesion). 
• New anti -cancer therapy . 
• Investigator ’s RECIST assessments. 
• CA-125 results. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 44 of 62  
 6. SAFETY ANALYSES  
The main safety summary tables  will use data from the Safety  population. Patients  will be 
analyzed according to the actual study drug received .  
If the primary efficacy endpoint (PFS BIRC) is only statistically significant in patients with 
FRα high expression but not in the ITT, the following subgroup tables will also  be prepared 
for patients with FR α high expression.   
• Exposure 
• Treatment -emergent adverse events (TEAEs)  
• Serious TEAEs  
• Lab shift tables  
• Clinically significant values in liver function tests  
Listings will be provided for patients  in the Safety population. T he actual study drug received 
will be displayed on the listing . 
 
6.1. Exposure  
Summary  tables will be provided with the following information. 
Exposure to IMGN853, paclitaxel, topotecan, and PLD will be summarized in tables with 
descriptive statistics for the number of doses received, the number of cycles received, 
duration of dosing (weeks), total cumulative dose ( mg), absolute dose intensity (mg/kg/dose 
for IMGN853, calculated as total cumulative dose [ mg])/number of valid drug administration 
records (performed infusions or held infusions)/AIBW (kg); mg/m2/dose for remaining 
investigation al products, calculated as total cumulative dose (mg)/number of valid drug 
administration records (performed infusions or held infusions)/BSA (m2), and relative dose 
intensity ( percentage of planned, calculated as [ absolute dose intensity/6] × 100 for 
IMGN 853, [absolute dose intensity/80] × 100 for paclitaxel, [absolute dose intensity/40] × 
100 for PLD, [absolute dose intensity/1.25] × 100 for topotecan 1.25 mg/m2, [absolute dose 
intensity/4] × 100 for topotecan 4 mg/m2). 
The number of infusions with dose decreased, infusions interrupted, and dose delayed will also be summarized by study drug. The number of infusions with the rate of infusion decreased will also be summarized for the IMGN853 study-drug groups. 
The number of patients who received IMGN85 3 pivotal lots,  non-pivotal lots, and different  
lot numbers will be summariz ed. 
A listing will be provided with the information from all study drug administration eCRFs 
over the t reatment period .  
For Stage 1, a separate listing will be provided with the information from all study drug administration eCRFs.  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 45 of 62  
 6.2. AEs 
AEs will be documented on the AE eCRF and monitored continuously throughout the study 
from the time of informed consent until 30 days after the patient’s last study drug or until the 
event has res olved, stabilized, or returned to baseline. AEs attributed to study procedures, 
including those events that occur prior to the first dose, should also be documented on the AE 
eCRF.  
AE data are available to I mmunoGen from 2 sources, the eCRFs and the serious adverse 
event ( SAE ) forms . While reconciliation will be performed, the production of data 
summaries and listings will be based on the data collected on the eCRF.  Pre-treatment AEs are defined as AEs with an onset date pr ior to the first dose of study drug. 
TEAEs are defined as AEs  with an onset date on or after the first dose of study drug, and 
within 30 days of the last dose of study drug or prior to the start of a new anti- cancer 
treatment, whichever occurs first . Medical history conditions that exist before the initiation of 
study drug but worsen in severity during the study will also be recorded on the AE eCRF as 
an AE and will be included as treatment -emergent in the summary tables and listings .  
The adverse events wi ll be coded using MedDRA (Version 18.1 or later ), associating 
lower -level terms with PT  and SOC  by the primary hierarchy. The tables will display the 
counts and percentages  of patients who reported at least 1 TEAE in each SOC  represented in 
the AE data. Within each SOC , the tables will display the counts and percentages of patients 
reporting at least 1 TEAE as designated by the PT . 
AEs are graded using Common Terminology Criteria for Adverse Events (CTCAE) 
Version  4.03. AE summaries may include summaries fo r all AEs and by the maximum 
CTCAE grade for the item being summarized ( ie, SOC  or PT ). In these cases, the outputs 
will include a row for All Grades as well as rows for the 5 potential CTCAE grades, Grade 1 
(Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life threatening or disabling), or 
Grade 5 (Death) . AEs missing a severity grade will not be included in the Grade 1-5 rows of 
the tables . An AE reported by a patient more than once will be represented in the most severe 
category.  
The following AE summar y tables  will be produced:   
• An overall summary of s afety will summarize the numbers of patients with 
TEAEs of each grade and the number of patients who died during the study or within 30 days of last dose. 
• All TEAE .s 
• Serious TEAEs . 
• Non-Serious TEAEs ( ie, TEAEs excluding SAEs). 
• Grade 3 or higher TEAEs . 
• TEAEs leading to drug withdrawal. This subset includes TEAEs with an action taken of drug p ermanently discontinued. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 46 of 62  
 • TEAEs related to study drug. This table will include TEAEs with a drug 
relationship of possibly r elated, probably r elated, or definitely r elated.  The table 
will include TEAEs with missing drug relationships. An AE reported by a patient 
more than once will be included in this table if at least 1 of the drug association 
grades is 1 of the grades listed here.  
• Serious, r elated TEAES . This subset includes all serious TEAEs with a drug 
relationship of possibly r elated, probably r elated, or definitely r elated. The table 
will include serious TEAEs with missing drug relationships. An AE reported by a patient more than once will be included in this table if at least 1 of th e drug 
association grades is 1 of the grades listed here. 
• Deaths on study or within 30 days of the l ast dose. 
The following AE listings will be produced:  
• All p re-treatment AEs will be listed.  
• All AEs, sorted chronologically by patient . This listing includes SOC , PT, onset 
and end dates, and other relevant information. 
• Serious TEAEs, sorted chronologically within patient. 
• TEAEs leading to drug withdrawal. This subset includes TEAEs with an a ction 
taken of drug p ermanently discontinued. 
• TEAEs related to study drug. This listing will include TEAEs with a drug 
relationship of possibly r elated, probably r elated, or definitely r elated. This listing  
will include TEAEs with missing drug relationships .  
• Serious TEAEs related to study drug. This listing will include serious TEAEs 
with a drug relationship of possibly r elated, probably r elated,  or definitely r elated. 
This listing  will include serious TEAEs with missing drug relationships.  
• TEAEs resulting in  death . This  listing includes TEAEs with a CTCAE grade of 
Grade 5 ( death) or TEAEs with an outcome of f atal. 
• All deaths , with an indication of whether the death occurred on study or within 
30 days of the last dose. 
The following groupings of TEAEs will be generated as part of the focused analysis of safety:  
• Ocular TEAEs  
− A list of PTs  for ocular AEs will be provided and finalized by the Sponsor 
before the final database lock.  
• Peripheral neuropathy TEAES 
− A list of PTs  for peripheral neuropathy AEs will be provided and finalized by 
the Sponsor before the final database lock.  
• Pneumonitis  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 47 of 62  
 For each of the focused safety analysis groups, the following summar y tables will be 
produced: 
• TEAEs by SOC, PT, and maximum CTCAE grade. 
• Related TEAEs by SOC, PT, and maximum CTCAE grade. 
• Serious TEAEs by SOC, PT, and maximum CTCAE grade. 
• Related serious TEAEs by SOC, PT, and maximum CTCAE grade. 
Additionally, a table will be produced which contains the following for each of the focused 
safety analysis groups: 
• The number of patients  with at least 1 TEAE in each group, presented by 
treatment arm . 
• Time to first onset of each group of TEAEs . 
• Action taken with study drug with respect to each group of TEAEs. 
For the focused safety analysis, the following listings will be produced: 
• Ocular TEAEs . 
• Peripheral neuropathy TEAEs. 
• Pneumonitits  TEAE. 
For Stage 1, the following AE listings will be produced: 
• All pre -treatment AEs.  
• All AEs, sorted chronologically within patient. This listing includes SOC , PT, 
onset and end dates, and other relevant information. 
• Serious TEAEs, sorted chronologically within patient. 
• TEAEs leading to drug withdrawal. This subset includes TEAEs with an action taken of drug p ermanently discontinued. 
• TEAEs related to study drug. This listing will include TEAEs with a drug relationship of possibly r elated, probably r elated, or definitely r elated. The listing  
will include TEAEs with missing drug relationships .  
• Serious TEAEs related to study drug. This lis ting will include serious TEAEs 
with a drug relationship of possibly r elated, probably r elated, or d efinitely r elated. 
This listing  will include serious TEAEs with missing drug relationships.  
• TEAEs resulting in death. This listing includes TEAEs with CTCA E Grade 5 
(death) or TEAEs with an outcome of f atal. 
• All deaths.  
 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 48 of 62  
 6.2.1. Fresh Biopsy Patient TEAE  
Summary of adverse events, not necessarily TEAEs, experienced within 7 days of biopsy 
will be generated by SOC , PT and CTCAE grade .  A listing of AEs experienced within 7 
days of biopsy will also be generated. 
6.2.2. Infusion -related Reactions  
A summary table of infusion- related reactions , occurring 1 day or within 3 days of any 
infusion  will be generated  by SOC, PT,  and CTCAE grade .  A listing of infusion- related 
reactions occurring within 3 days after any infusion will also be generated.  A list of the PT s 
for infusion related reactions will be determined by the Sponsor prior to final database lock. 
6.3. Clinical Laboratory Results  
Laboratory test results (including hematology, coagulation, serum chemistry, and urinalysis) 
and abnormal laboratory values will be presented in data listings.  
CTCAE  Version 4.03 lab oratory  grades will also be presented . CTCAE grades will be 
derived based on laboratory results, and will not factor in clinical evaluations .  
Shift tables summarizing the changes from baseline in severity of lab oratory  grades will be 
provided for laboratory  parameters graded according to CTCAE Version 4.03. Grade 3 or 
higher lab oratory  values will be summarized b ased on the worst grade observed on study.  
Clinically significant values in liver function tests will be summarized by  the following 
categories , using the maximum value while on study drug. The denominator for the 
summaries will be the number of patients  who had at least 1 non-missing value during 
treatment . The categories for each test are not mutually exclusive:  
• Aspartate aminotransferase (AST)  
− > 3 × ULN  
− > 5 × ULN  
− > 10 × ULN  
− > 20 × ULN  
• Alanine Aminotransferase (ALT)  
− > 3 × ULN  
− > 5 × ULN  
− > 10 × ULN  
− > 20 × ULN  
• AST or ALT  
− > 3 × ULN  
− > 5 × ULN  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 49 of 62  
 − > 10 × ULN  
− > 20 × ULN  
• Total bilirubin (TBL)  
− > ULN  
− > 2 × ULN  
• Alkaline phosphatase (ALP) 
− > 1.5 × ULN  
• (AST or ALT) and TBL (concurrent) − AST or ALT > 3  × ULN and TBL > 1.5 × ULN  
− AST or ALT > 3  × ULN and TBL > 2  × ULN  
• (AST or ALT) and ALP and TBL (concurrent)  
− AST or ALT > 3  × ULN and ALP < 2  × ULN and TBL > 2  × ULN  
Results from pregnancy tests will be provided in listings.  
6.4. Vital Signs  
Vital signs (including temperature, pulse rate, systolic blood pressure, diastolic blood 
pressure, respiratory rate , and weight) will be presented in data listings.  
Summaries of actual values and changes from baseline will be presented by treatment group for each assessment time point, beginning with the Cycle 1 Day 1 Completion of Infusion time point.  
6.5. ECGs  
ECG results ( rhythm, heart r ate, PR interval, RR interval, QRS interval, QT interval, QTcF 
interval, and classification of w ithin normal l imits, abnormal, not c linically significant, and 
abnormal, c linically s ignificant will be presented in data listings . If a different correction for 
QT is captured in the eCRF, that QTc will be reported in the listing for that patient with QTcF.  
The number and percentage of patients in the following non- mutually exclusive categories 
will be summarized by visit:  
• QTc > 450 ms  
• QTc > 480 ms 
• QTc > 500 ms 
• QTc change from baseline > 30 ms 
• QTc change from baseline > 60 ms 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 50 of 62  
 For the purpose of QTc analysis, derived values using QT and RR will be used if QTcF or 
QTcB are not collected on the eCRF:   
𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄=𝑄𝑄𝑄𝑄
√𝑅𝑅𝑅𝑅3  
𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄=𝑄𝑄𝑄𝑄
√𝑅𝑅𝑅𝑅 
6.6. Concomitant Medications  
All medications and supportive therapy taken within 4 weeks prior to Cycle 1 Day 1 and through 30 days after last study treatment must be recorded on the appropriate eCRF. The 
identity of all medications, dosage, route of administration, frequency, duration of 
administration, and indication for use will be recorded in the appropriate sections of the eCRF.  
Prior medications are defined as medications with a stop date prior to the first dose of study drug.  
Concomitant medications ar e defined as medications which are taken during the course of 
study treatment and within 30 days of the last dose of study drug, as follows:  
• For Stage 1, medications started after the first dose of study drug and within 
30 days of the last dose of study drug are considered concomitant medications .  
• Medications started before the first dose of study drug , but with a stop date after 
the first dose of study drug and within 30 days of the last dose of study drug  will 
be considered concomitant medications.  
• Medications started before the first dose of study drug  that are ongoing will be 
considered concomitant medications. 
• Medications started after the first dose of study drug and within 30 days of the last 
dose of study drug or before the start of a new anti -cancer treatment, whichever 
occurs first, are considered concomitant medications.  
• Medications started before the first dose of study drug , but with a stop date after 
the first dose of study drug and within 30 days of the last dose of study drug  or 
prior to the start of a new anti -cancer treatment, whichever occurs first, will be 
considered concomitant medications .  
• Medications started before the first dose of study drug  that are ongoing will be 
considered concomitant medications. 
Prior and concomitant medications will be coded using the September 2015 or later version 
of World Health Organization drug dictionary ( WHO Drug ). Summary tables will be 
provided for prior and concomitant medications.  
Summary table s will be organized to display the anatomical main class of each coded 
medication  (ATC L evel 1 term)  and, within that, the pharmacological subgroup ( ATC 
Level 3 term ) of the coded medication . The summary table will display number and 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 51 of 62  
 percentage of patients  who reported using at least 1 medication  in each represented 
pharmacological subgroup. If a patient has more than 1 medication in the subgroup, t he 
patient  will be counted only once. 
A complete listing of medications will be generated  by patient. The listing will indicate 
which  medication s are prior and which are concomitant . The listing  will display entries from 
the concomitant medications form, ordered within patient by s tart date. The listing will 
display the recorded term from the eCRF and the WHO Drug anatomical main class  (ATC 
Level 1 term)  and pharmacological subgroup (ATC L evel 3 term) . 
6.7. Concomitant Procedures  
All procedures within 4 weeks of Cycle 1 Day 1 and through 30 days after last study 
treatment must be recorded on the appropriate eCRF .  
Prior procedures are defined as occurring before the first dose of study drug (by procedure date) .  
Concomitant procedures are defined as procedures with a procedure date on or after the first dose of study drug, and within 30 days of the last dose of study drug, as follows:  
• For S tage 1, procedures  occurring on or after the first dose of study drug, and 
within 30 days of the last dose of study drug (by procedure date).  
• Procedures  are defined as concomitant procedures with a  procedure date on or 
after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti- cancer treatment, whichever occurs first.  
Prior and conco mitant procedures will be coded using MedDRA (Version 18.1 or later), 
associating lower -level terms with PT  and SOC  by the primary hierarchy. S ummary tables 
will be provided for prior and concomitant procedures. The tables will display number and percentage of patients who reported at least 1 procedure in each SOC  represented in the 
eCRF  data. Within each SOC , the tables will display number and percentage of patients 
reporting at least 1 concomitant procedure as designated by PT . 
A complete listing of procedures will be generated . The listing will indicate which  
procedures are prior and which are concomitant. The listing will display entries from the 
concomitant procedures form, ordered within patient by date of procedure. The listing will display the recorded term from the e CRF and the SOC  and PT .  
6.8. Ophthalmic Examinations  
Ophthalmic Examinations are collected at the Screening, End-of- Treatment , and 
30-Day Follow- up Visits . Results of the ophthalmic examinations will be presented in data 
listings .  
A summary table will be provided of the overall e xam r esult ( within normal l imits, abnormal, 
not c linically significant, and abnormal, c linically significant) by treatment group and visit. 
6.9. Ocular Sy mptom Ass essments 
Results of the a cular assessments will be presented in data listings .  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 52 of 62  
 A summary table will be provided of the ocular s ymptom a ssessment ( within normal l imits, 
abnormal, not c linically significant, and abnormal, c linically significant) by treatment group 
and visit. 
6.10. Corticost eriod and Lubricating Eye Drop Compliance  
All compliance information collected on the eCRF will be presented in data listings.  
6.11. Transfusions  
All transfusions recorded on the eCRF will be presented in data listings. Transfusions will be 
coded using MedDRA Version 18.1 or later.  
6.12. Physical Examination  
Physical e xamination results will be presented in data listings .  
6.13. Pulmonary Function Tests   
Pulmonary function test  results will be presented in data listings .  
6.14. Pulse Oximetry  
Pulse oximetry data were  collected only for patients in Stage 1, and will be presented in a 
data listing.  
6.15. ECOG PS 
ECOG PS results will be presented in data listings .  
6.16. ECHO CARDIOGRAM/MU LTIPLE GATED ACQUISITION 
SCANS  
Echocardiogram (ECHO)/multiple gated acquisition (MUGA)  scans are taken on ly for 
patients receiving PLD. All ECHO/MUGA results will be presented in data listings . 
Summaries of actual values and changes from baseline will be presented for the PLD treatment group for each assessment time point, beginning with Cycle 4 Day 1.  
 
  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 53 of 62  
 7. PRO  
Analyses for PRO, including quality of life and healthcare resource utilization , will be 
covered by a separate, independent analysis plan by the PRO vendor, in collaboration with 
ImmunoGen. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 54 of 62  
 8. IMMUNOGENICITY 
The ADA analyses, including the impact of immunogenicity on PK, will be covered by a 
separate, independent analysis plan  (see Section  10).  
Impact of immunogenicity on safety and efficacy will be explored. A by patie nt TEAE listing  
for those patients determined seropositive for IMGN853 antibodies will be produced. Summary of TEAEs experienced within 1 and 3 days of ADA+ will be generated for those 
patients who sero-convert following the first dose of mirvetuximab soravtansine.  Efficacy 
will be analysed by seroconversion status for patients treated with IMGN853. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 55 of 62  
 9. BIOMARKERS  
The exploratory biomarker analyses for this study will be covered by a separate, independent 
analysis plan .  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 56 of 62  
 10. PHARMACOKINETICS  
The PK analyses will be covered by a separate, independent analysis plan . The  PK analyses 
will be performed using the plas ma collected for PK purposes. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 57 of 62  
 REFERENCES  
Zucker DM, Restricted mean life with covariates: modification and extenstion of a useful survival 
analysis method, J Am Stat Assoc 93: 702 -709, 1998 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 58 of 62  
 APPENDIX 1:  TEMPLATE SAS® CODE  
This appendix provides template SAS® code ( Version 9.3 or higher) that will be used for 
analysis.  
Template code for the ORR, DCR, and GCIG CA -125 response estimates along with the 95% 
CIs: 
proc freq data= AD_RESP ; 
by TRTP ; 
tables AVAL  / binomial alpha=0.05; 
run; Template code for the stratified CMH test: proc freq data=AD_RESP; 
tables STRATUM* TRTP *AVAL  / cmh; 
run; 
Template code for the unstratified chi -squared test:  
proc freq data=AD_RESP; tables TRTP*AVAL / chisq;  
run; 
Template code for median time- to-event estimates along with 95% confidence intervals: 
proc lifetest data=AD_TTE;  
time AVAL*CNSR(1);  
strata TRTP;  
run; 
Template code for the stratified log -rank test:  
proc lifetest data=AD_TTE;  
time AVAL*CNSR(1);  
strata STRATUM / group=TRTP;  
run; Template code for the unstr atified log -rank test:  
proc lifetest data=AD_TTE;  
time AVAL*CNSR(1);  
strata TRTP;  
run; 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 59 of 62  
 Template code for the stratified Cox proportional hazards model: 
proc phreg data=AD_TTE; 
 class trtp; 
model AVAL*CNSR(1) = TRTP / risklimits;  
strata STRATUM;  
run; 
Templa te code for the unstratified Cox proportional hazards model:  
proc phreg data=AD_TTE; 
model AVAL*CNSR(1) = TRTP / risklimits;  
run; 
where: 
AD_RESP i s the name of the ADaM  dataset  used for response analysis 
AD_TTE is the name of the ADaM dataset used for time -to-event analysis  
TRTP  is a variable containing the treatment used for analysis .  
AVAL  is a variable containing the value for analysis (eg,  objective response or time to death )  
CNSR is a variable indicating whether the AVAL is censored (1=censored, 0=non-censored) 
STRATUM is a v ariable containing all levels of the randomization stratification factors  
  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 60 of 62  
 APPENDIX 2:  MONTE- CARLO SIMULATION REPORT  
This appendix describes the assumptions, algorithms, and results of Monte- Carlo simulation 
studies evaluatin g the type I error and power of this study under different scenarios. 
Randomization and S tratification  
The study will randomize 333 patients over a period of 21 months with a randomization ratio 
of 2:1 (222 to the IMGN853 arm and 111 to the IC chemotherapy  arm) . The randomization 
will be stratified by the following factors: 
• FRα expression level by IHC (≥ 75% tumor staining at ≥  2+ intensity vs ≥ 50% 
and < 75% tumor staining at > 2+ intensity ). 
• Number of prior lines of therapy (1 or 2 vs 3). 
• IC chemotherapy (Pac, PLD or Topo). 
Interim Futility Analysis  
The study will have an interim futility analysis when 80 PFS events have occurred in the ITT population. If the hazard ratio (HR, IMGN853 relative to IC chemotherapy) estimate for PFS 
is greater th an 1 in both the ITT population and the FR α high expression subgroup, the study 
will be stopped for futility . Otherwise, the study will continue to full enrollment of 
333 patients in the ITT population.  
Primary Efficacy Endpoints  
The final analysis will o ccur when at least 236 PFS events have occurred in the ITT 
population and 2 primary efficacy endpoints will be analyzed as follows: 
• PFS in the ITT population. 
• PFS in the FR α high-expression subgroup. 
Hypothesis Testing  
The null hypotheses are as follows: 
• H01: the survival function for PFS is the same between the IMGN853 arm and the 
IC chemotherapy  arm in the ITT population, and  
• H02: the survival function for PFS is the same between the IMGN853 arm and the 
IC chemotherapy  arm in the FR α high- expression subgroup.  
And the alternative hypotheses are as follows: 
• Ha1: the survival function for PFS is different between the IMGN853 arm and the 
IC chemotherapy  arm in the ITT population, and  
• Ha2: the survival function for PFS is different between the IMGN853 arm and the 
IC chemotherapy  arm in the FR α high- expression subgroup.  
Each endpoint will be tested using a stratified log -rank test (stratified by the stratification 
factors used in randomization).  
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 61 of 62  
 Multiple Testing Procedure 
The Hochberg procedure will be used to control the study- wise type I error . Assume the 
log-rank p- values for the 2 endpoints are P (1) and P (2) (P(1) ≤ P(2)). Let H 0(1) be the null 
hypothesis corresponding to P (1) and H 0(2) the hypothesis corresponding to P(2). The 
Hochberg will first test P (2) against 0.05.  
• If P (2) ≤ 0.05 , then reject both H 01 and H 02 and claim statistical significance in both 
endpoints.  
• If P (2) > 0.05, then P (1) will be tested against 0.025.  
− If P (1) ≤ 0.025, then reject H 0(1) and claim statistical significance for that 
endpoint.  
− If P (1) > 0.025, then no null hypothesis will be rejected.  
This Hochberg procedure is illustrated as follows : 
 P(2)  ≤ 0.05 
No Null hypothesis 
is rejectedReject H 0(1)STOP
& 
 reject both H 01 & H 02 
NOYES
P(1)  ≤ 0.025NO
YES
  
 
Simulation Assumptions  
The following assumptions are used in the Monte- Carlo simulation studies . 
• Monthly enrollment rate increases linearly during first 6 months, followed by 
uniform enrollment during months 7-21. 
• PFS follows exponential distribution for the IC chemotherapy  arm, 
FRα medium-expression subgroup in the IMGN853 arm, and 
FRα high-expression subgroup in the IMGN853 arm, respectively.  
• Censoring process follows an exponential distribution with 1- year censoring rate 
of 20% for both arms. 
ImmunoGen, Inc. / Protocol: 0403  
Novella Clinical (Confidential) Project # OXA66954  
  Page 62 of 62  
 • Ratio of number of patients between FR α high expression and medium expression 
is 2:1 or 1:1. 
• Median PFS for the IC chemo therapy  arm is 3.5 months. 
− Number of trials under each scenario is 10000. 
Simulation Results  
Under different scenarios, the probability of stopping for futility at interim and the 
probability of rejecting H 01 (for the ITT population) and H 02 (for FR α high-expression 
subgroup) are summarized in Table 9 .  If the FR α high/medium ratio is 2:1, there is 39% 
probability of stopping for futility at interim if both null hypotheses H 01 and H 02 are true and 
the overall type I error is controlled at 4.0%. Using the Hochberg procedure, the study will have a 96% and 91% power to detect a median PFS of 6.0 months in the IMGN853 arm 
(HR = 0.583) in the ITT population and FR α high-expression subgroup, respectively. If the 
FRα high/medium ratio is 1:1, there is 37% probabi lity of stopping for futility at interim if 
both null hypotheses H
01 and H 02 are true and the overall type I error is controlled at 3.6%. 
Using the Hochberg procedure, the study will have a 96% and 81% power to detect a median 
PFS of 6.0 months in the IMGN853 arm (HR = 0.583) in the ITT population and FRα high-expression subgroup, respectively. 
Table 9: Summary of Monte- Carlo Simulations  
True M edian PFS (months)  FRα High/ 
Medium 
Ratio  Probability of  
Stopping for 
Futility at 
Interim 
Analysis Probability of 
Rejecting  
IC 
Chemo  IMGN853 
(FRα medium)  IMGN853 
(FRα high)  H01 H02 
3.5 3.5 3.5 2:1 39% 2.1% 1.9% 
3.5 3.5 6.0 2:1 2.1% 75% 85% 
3.5 4.5 6.0 2:1 1.2% 89% 89% 
3.5 5.0 6.0 2:1 0.8% 93% 90% 
3.5 5.5 6.0 2:1 0.6% 95% 90% 
3.5 6.0 6.0 2:1 0.5% 96% 91% 
3.5 3.5 3.5 1:1 37% 1.9% 1.7% 
3.5 3.5 6.0 1:1 3.4% 51% 72% 
3.5 4.5 6.0 1:1 1.8% 80% 77% 
3.5 5.0 6.0 1:1 1.2% 88% 79% 
3.5 5.5 6.0 1:1 0.8% 93% 80% 
3.5 6.0 6.0 1:1 0.5% 96% 81% 
Chemo  = chemotherapy; FR α = folate receptor alpha; IC  = Investigator ’s choice; PFS  = progression- free 
survival.  
 